# Chapter 111: Opioid Withdrawal

# The Biological and Neurological Basis of Opioid Withdrawal

## Introduction

Opioid withdrawal is a characteristic syndrome that emerges following the cessation or significant reduction of chronically administered opioids in an individual who has developed physical dependence (Hosztafi, 2011; Dunn et al., 2023). This altered physiological state, produced by the repeated administration of opioids, necessitates the continued presence of the drug to prevent the appearance of a distressing and often debilitating constellation of signs and symptoms (Hosztafi, 2011; Franklin, 1995). The syndrome is a core component of opioid use disorder, a chronic, relapsing illness characterized by compulsive drug-seeking and use despite adverse consequences (Schuckit, 2016; Dydyk et al., 2021). While the clinical presentation of opioid withdrawal is well-documented, encompassing a wide range of physical, affective, and cognitive disturbances, the underlying biological and neurological mechanisms are complex and involve profound neuroadaptations across multiple brain systems (Kosten & George, 2002; Trujillo, 2012).

The experience of opioid withdrawal is profoundly aversive and is frequently cited by patients as a primary driver for continued opioid use and a significant barrier to achieving abstinence (Dunn et al., 2023; Kosten & George, 2002). Symptoms can manifest within hours of the last dose and typically include restlessness, muscle and bone pain, insomnia, diarrhea, vomiting, cold flashes with piloerection ("goose bumps"), and involuntary leg movements (Hosztafi, 2011; Dunn et al., 2023). These are often accompanied by severe psychological distress, including dysphoria, anxiety, irritability, and an intense craving for the drug (Dunn et al., 2023; Sivolap, 2010). While the acute phase of withdrawal generally subsides within a week, a protracted syndrome with persistent signs of dysphoria, anxiety, and sleep disturbances can last for months or even years in some individuals (Hosztafi, 2011; Ghaffarinejad et al., 2012).

Understanding the biological basis of this syndrome is critical for developing effective treatments and for conceptualizing opioid dependence as a chronic brain disease rather than a moral failing (Kosten & George, 2002; Borowski, 2013). The neurological changes that precipitate withdrawal are not merely the inverse of the drug's acute effects but represent a complex homeostatic recalibration of the central nervous system (CNS) (Koch et al., 2003). Chronic opioid exposure leads to adaptations in endogenous opioid pathways as well as in non-opioid neurotransmitter systems, including the glutamate, norepinephrine, dopamine, and serotonin systems (Rasmussen, 2002; Kosten & George, 2002). The abrupt removal of the opioid unmasks these adaptations, resulting in a state of widespread neuronal hyperexcitability that manifests as the clinical withdrawal syndrome (Saitz, 1998; Thompson et al., 2021).

This chapter aims to provide a comprehensive overview of the biological and neurological foundations of opioid withdrawal. Drawing upon the available research literature, it will explore the neuropharmacological changes, implicated brain regions and circuits, and the cellular and molecular mechanisms that drive this complex condition. By synthesizing evidence from studies of opioids, as well as drawing parallels from related neurobiological states such as alcohol and benzodiazepine withdrawal, depression, and anxiety, this chapter will construct a detailed, evidence-based picture of the neurobiology of opioid withdrawal and its implications for treatment and recovery.

## Neurobiological Systems

The clinical manifestations of opioid withdrawal are the direct result of profound and widespread dysregulation across multiple neurobiological systems. Chronic exposure to exogenous opioids forces the brain to adapt its homeostatic mechanisms to maintain a semblance of equilibrium in the drug's presence (Koch et al., 2003). When the drug is withdrawn, these adaptive changes are unmasked, leading to a state of hyperexcitability that drives the withdrawal syndrome (Saitz, 1998; Thompson et al., 2021). This process involves not only the endogenous opioid system but also critical non-opioid neurotransmitter systems that regulate mood, arousal, stress, and reward.

### The Endogenous Opioid System and Receptor Neuroadaptation

Opioids exert their primary effects—including analgesia, euphoria, and respiratory depression—by acting as agonists at specific opioid receptors, primarily the mu (μ), kappa (κ), and delta (δ) receptors (KuKanich & Wiese, 2015; Kosten & George, 2002). These receptors are distributed throughout the CNS and peripheral tissues, including the gastrointestinal tract (KuKanich & Wiese, 2015; Melchior et al., 2020). Chronic stimulation of these receptors by exogenous opioids, such as heroin or morphine, leads to a series of neuroadaptive changes designed to counteract the drug's persistent effects (Koch et al., 2003). This process underlies the phenomena of tolerance, where increasing doses are needed to achieve the same effect, and physical dependence, the state that gives rise to withdrawal upon cessation (Kosten & George, 2002; Trujillo, 2012).

One of the key mechanisms of neuroadaptation is the downregulation and desensitization of opioid receptors (Koch et al., 2003). Chronic agonist exposure can lead to a reduction in the number of receptors available on the cell surface and a decoupling of the remaining receptors from their intracellular signaling pathways, such as the G-protein-cAMP system (Koch et al., 2003; Trujillo, 2012). This reduced receptor responsivity contributes to tolerance (Koch et al., 2003). Furthermore, the system develops a compensatory upregulation of the cAMP pathway to counteract the inhibitory effect of opioids. When the opioid is removed, this "overshoot" in the cAMP system contributes to the hyperexcitability characteristic of withdrawal (Kosten & George, 2002). This cellular-level hyperactivity is a foundational element of the withdrawal state.

### Glutamatergic System Hyperactivity

While adaptations in the opioid system are crucial, a key driver of the withdrawal syndrome is hyperactivity in the brain's primary excitatory neurotransmitter system, mediated by glutamate (Rasmussen, 2002). Glutamate acts on several receptor types, most notably the N-methyl-D-aspartate (NMDA) receptor, which is critically involved in synaptic plasticity, learning, and memory, as well as excitotoxicity (Trujillo, 2012; Pujol & Puel, 1999). Chronic opioid exposure leads to an upregulation of the NMDA receptor system, a compensatory response to the persistent inhibitory tone imposed by opioids (Trujillo, 2012; King et al., 2005).

During withdrawal, the sudden removal of opioid-mediated inhibition unmasks this sensitized glutamatergic system, leading to a state of profound neuronal hyperexcitability (Rasmussen, 2002; Becker & Redmond, 2002). This glutamate hyperactivity is thought to be a major contributor to many withdrawal symptoms, including anxiety, agitation, hyperalgesia (increased sensitivity to pain), and potentially seizures (Rasmussen, 2002; Trujillo, 2012; Becker & Redmond, 2002). The involvement of NMDA receptors in withdrawal is supported by evidence that NMDA receptor antagonists can attenuate the development of opioid tolerance and the severity of withdrawal symptoms (Trujillo, 2012). This glutamatergic surge can be conceptualized as a form of excitotoxicity, a process where excessive neuronal stimulation leads to cellular damage, which has been implicated in a range of neurological conditions from epilepsy to anoxia (Pujol & Puel, 1999; Beghi et al., 2009).

### Noradrenergic System Dysregulation and Autonomic Hyperactivity

One of the most clinically apparent features of opioid withdrawal is profound autonomic hyperactivity, manifesting as tachycardia, hypertension, sweating, piloerection, and diarrhea (Hosztafi, 2011; Dunn et al., 2023). This sympathetic storm is largely driven by the dysregulation of the noradrenergic system, particularly neurons originating in the locus coeruleus (LC) (Rasmussen, 2002). The LC is a brainstem nucleus that is the principal source of norepinephrine (NE) in the brain, playing a key role in arousal, vigilance, and the stress response (Rasmussen, 2002).

LC neurons are tonically inhibited by endogenous opioids and are highly sensitive to exogenous opioids (Kosten & George, 2002). Chronic opioid administration leads to an adaptive upregulation of the cAMP pathway within LC neurons to counteract this inhibition (Kosten & George, 2002). During withdrawal, the removal of opioid inhibition results in a massive, unopposed firing of LC neurons, releasing a flood of NE throughout the CNS and periphery (Rasmussen, 2002). This noradrenergic surge is directly responsible for many of the somatic symptoms of withdrawal, including restlessness, anxiety, increased heart rate and blood pressure, and gastrointestinal distress (Pergolizzi et al., 2018; Dunn et al., 2023). The mechanism is analogous to the rebound sympathetic hyperactivity seen after the abrupt withdrawal of other CNS depressants, such as clonidine or beta-blockers (Hart & Anderson, 1981; Karssemeijer et al., 2021). The central role of this noradrenergic hyperactivity is underscored by the efficacy of α2-adrenergic agonists like clonidine and lofexidine, which act to suppress LC firing and are used to ameliorate withdrawal symptoms (Kleber, 2007; Pergolizzi et al., 2018).

### Dopaminergic System and Anhedonia

The mesocorticolimbic dopamine system, originating in the ventral tegmental area (VTA) and projecting to areas like the nucleus accumbens (NAc) and prefrontal cortex, is the brain's primary reward pathway (Wand, 2008; Glass, 1990). Opioids, like many drugs of abuse, increase dopamine release in the NAc, which is thought to mediate their euphoric and reinforcing effects (Kosten & George, 2002; Miyasato, 2013). Chronic opioid use leads to neuroadaptations that blunt this reward system (Wand, 2008).

During withdrawal, there is a marked decrease in dopamine levels in the NAc, which contributes significantly to the negative affective state of withdrawal, particularly dysphoria and anhedonia (the inability to experience pleasure) (Ozdemir et al., 2023; Kosten & George, 2002). This state of reward deficiency is a powerful motivator for relapse, as the individual seeks to restore the hedonic tone by taking the drug again (Glass, 1990; Wand, 2008). The anhedonia and loss of motivation seen in opioid withdrawal share phenomenological and likely neurobiological overlap with symptoms of major depressive disorder (MDD), where dysregulation of dopamine and other monoamines is also implicated (Bains et al., 2021; Sarris et al., 2014). The depressive symptoms of withdrawal, such as low mood, fatigue, and loss of interest, can be severe and persistent (Hosztafi, 2011; Fava, 2003).

### Other Implicated Systems: Serotonin, GABA, and Stress Hormones

The serotonin (5-HT) system is broadly involved in regulating mood, sleep, and appetite, and its dysregulation is a cornerstone of theories of depression and anxiety (Sarris et al., 2014; Bains et al., 2021). During opioid withdrawal, alterations in serotonergic transmission likely contribute to symptoms such as anxiety, irritability, and sleep disturbances (Ozdemir et al., 2023; Perananthan & Buckley, 2021). The anxiety and panic attacks that can occur during withdrawal share features with primary anxiety disorders, suggesting a common neurobiological substrate (Ranganathan & Beitman, 1998; Munir & Takov, 2021).

The gamma-aminobutyric acid (GABA) system is the primary inhibitory neurotransmitter system in the CNS (Hertz et al., 2014). Its role is central to the action of benzodiazepines and alcohol, and withdrawal from these substances is characterized by a state of GABAergic hypofunction and resulting CNS hyperexcitability, which can lead to anxiety, insomnia, and seizures (Wright, 2020; Lasocka et al., 2020). While less central than in alcohol or benzodiazepine withdrawal, alterations in GABAergic function likely contribute to the overall state of hyperexcitability in opioid withdrawal, particularly symptoms like anxiety and restlessness (Yarlagadda et al., 2007; Hertz et al., 2014).

Finally, the stress response system, particularly the hypothalamic-pituitary-adrenal (HPA) axis, is profoundly activated during opioid withdrawal (Wand, 2008). This activation leads to the release of stress hormones like corticotropin-releasing factor (CRF) and glucocorticoids, which contribute to the anxiety, dysphoria, and general malaise of the syndrome (Wand, 2008; Anisman & Merali, 2003). This stress system activation is a key component of the negative emotional state that drives compulsive drug-seeking behavior in addiction (Vendruscolo & Koob, 2019).

## Genetic and Molecular Basis

The development of opioid dependence and the severity of the subsequent withdrawal syndrome are influenced by a complex interplay of genetic predispositions and molecular adaptations within the neuron. While environmental and psychosocial factors are significant, there is a clear biological basis for individual differences in vulnerability to addiction and the experience of withdrawal (Schuckit, 2016; Praveen et al., 2011). This section explores the genetic factors and the fundamental molecular and cellular mechanisms that underpin the opioid withdrawal state.

### Genetic Factors and Heritability

Addiction is recognized as a chronic brain disease with a significant genetic component (Schuckit, 2016; Borowski, 2013). Family, twin, and adoption studies suggest that genetic factors contribute substantially to the risk for developing substance use disorders, including opioid use disorder (O'Brien, 2005; Praveen et al., 2011). This heritability likely reflects variations in genes that influence neurotransmitter systems, stress reactivity, and personality traits such as impulsivity and risk-taking (Wand, 2008; Schuckit, 2016).

Although specific genes for opioid withdrawal severity are not fully elucidated in the provided literature, it is plausible that genetic polymorphisms in opioid receptors, their signaling components, or in the enzymes that metabolize opioids could influence the development of physical dependence and the intensity of withdrawal symptoms (Koch et al., 2003). For example, variations in the genes encoding dopamine or serotonin transporters, which are targets for antidepressant medications, could influence the severity of the affective components of withdrawal, such as depression and anxiety (Sarris et al., 2014). Similarly, genetic differences in the noradrenergic or glutamatergic systems could modulate the degree of autonomic hyperactivity and neuronal excitability seen during abstinence (Rasmussen, 2002). The multifactorial nature of opioid dependence suggests that a combination of multiple genes, each with a small effect, likely contributes to an individual's overall vulnerability (Praveen et al., 2011).

### Molecular Mechanisms of Neuroadaptation

At the molecular level, opioid withdrawal is a consequence of neuroplastic changes that occur in response to chronic drug exposure (Kosten & George, 2002). These changes represent the cell's attempt to maintain homeostasis in the face of persistent receptor stimulation (Koch et al., 2003). Key molecular events include alterations in receptor density, functionality, and intracellular signaling cascades.

**Opioid Receptor Regulation:** Chronic activation of opioid receptors, particularly the μ-opioid receptor, triggers several adaptive processes. One is receptor desensitization, where the receptor becomes less responsive to the agonist, often through phosphorylation by kinases like G-protein-coupled receptor kinases (GRKs) (Koch et al., 2003). This is followed by receptor internalization or downregulation, where the receptors are removed from the cell membrane, reducing the number available for activation (Koch et al., 2003; Trujillo, 2012). These processes are fundamental to the development of tolerance, requiring higher opioid doses to achieve the same analgesic or euphoric effect (Kosten & George, 2002; Koch et al., 2003).

**Intracellular Signaling Cascades:** Opioid receptors are G-protein-coupled receptors that, upon activation, inhibit the enzyme adenylyl cyclase, leading to a decrease in the intracellular second messenger cyclic adenosine monophosphate (cAMP) (Koch et al., 2003). In response to chronic opioid exposure, the cell compensates by upregulating the adenylyl cyclase/cAMP system (Kosten & George, 2002). This is a classic example of homeostatic adaptation. When the opioid is withdrawn, the inhibitory signal is removed, but the upregulated cAMP system remains, leading to a dramatic "overshoot" in cAMP levels (Kosten & George, 2002). This cAMP surge activates protein kinase A (PKA), which then phosphorylates numerous downstream targets, including ion channels and transcription factors, contributing to a state of increased neuronal excitability and the expression of withdrawal symptoms (Koch et al., 2003; Kosten & George, 2002).

**Role of NMDA Receptors:** The N-methyl-D-aspartate (NMDA) receptor, a key component of the glutamatergic system, plays a crucial role in opioid-induced neuroplasticity (Trujillo, 2012). Chronic opioid administration leads to an increase in the expression and function of NMDA receptors, contributing to both tolerance and the hyperexcitability seen in withdrawal (King et al., 2005; Trujillo, 2012). The activation of NMDA receptors allows an influx of calcium (Ca2+) into the neuron, which triggers a cascade of downstream signaling events (Söderpalm, 2002). This includes the activation of neuronal nitric oxide synthase (nNOS), leading to the production of nitric oxide (NO), a retrograde messenger that can further enhance glutamate release and contribute to synaptic plasticity (King et al., 2005). The hyperactivity of the NMDA receptor-Ca2+-nNOS pathway during withdrawal is a major driver of neuronal hyperexcitability and is implicated in symptoms like hyperalgesia (enhanced pain sensitivity) (King et al., 2005; Bekhit, 2010).

### Cellular and Synaptic Mechanisms

These molecular changes translate into alterations at the cellular and synaptic level. Neurons in key brain regions like the locus coeruleus (LC), ventral tegmental area (VTA), and nucleus accumbens (NAc) become hyperexcitable during withdrawal (Rasmussen, 2002; Kosten & George, 2002). This is reflected in increased spontaneous firing rates and enhanced responses to excitatory inputs.

Synaptic plasticity, the ability of synapses to strengthen or weaken over time, is profoundly affected. Long-term potentiation (LTP) and long-term depression (LTD) are cellular models of learning and memory that are modulated by drugs of abuse. The glutamatergic hyperactivity during withdrawal can alter these processes, potentially "stamping in" memories associated with drug use and withdrawal distress, which can contribute to craving and relapse (Trujillo, 2012; Sanchis‐Segura & Spanagel, 2006).

Furthermore, there is growing interest in the role of glial cells, such as astrocytes and microglia, in neuroinflammation and CNS disorders (Hertz et al., 2014). While not extensively detailed in the provided sources regarding opioid withdrawal specifically, processes involving cytokine release and immune activation have been linked to depression and stress responses, which are prominent features of withdrawal (Anisman & Merali, 2003; Anisman et al., 2005). It is plausible that neuroinflammatory processes contribute to the malaise, pain, and negative affective state of withdrawal, representing an area for future investigation.

## Brain Structure and Function

Opioid withdrawal is a systemic phenomenon, but its origins and principal manifestations are rooted in the dysfunction of specific brain regions and neural circuits. Chronic opioid use induces structural and functional neuroplasticity, and the abrupt cessation of the drug unmasks these adaptations, leading to a cascade of neurological and behavioral symptoms (Kosten & George, 2002). While the provided literature does not contain specific neuroimaging studies on opioid withdrawal, we can infer the involvement of key brain structures by examining their known roles in functions that are disrupted during withdrawal, such as reward, stress, arousal, and pain modulation, often drawing parallels from related conditions like depression and other substance use disorders.

### Key Brain Regions and Neural Circuits

**The Locus Coeruleus (LC) and the Ascending Noradrenergic System:** The LC, a small nucleus in the brainstem, is a critical hub for the physical symptoms of opioid withdrawal (Rasmussen, 2002). As the primary source of norepinephrine for the brain, it regulates arousal, vigilance, and the autonomic nervous system (Kosten & George, 2002). Opioids exert a powerful inhibitory effect on LC neurons. During chronic use, these neurons adapt to become tolerant. Upon opioid withdrawal, they become severely hyperactive, leading to a massive surge of norepinephrine release throughout the brain and spinal cord (Rasmussen, 2002). This noradrenergic storm is directly responsible for the classic autonomic signs of withdrawal, such as tachycardia, hypertension, sweating, and piloerection, as well as psychological symptoms like anxiety, agitation, and insomnia (Hosztafi, 2011; Dunn et al., 2023).

**The Mesolimbic Reward Pathway:** This circuit, comprising the ventral tegmental area (VTA), the nucleus accumbens (NAc), and their connections to the prefrontal cortex (PFC), is central to the rewarding effects of opioids and the development of addiction (Wand, 2008; Glass, 1990). Opioids increase dopamine release in the NAc, producing euphoria (Kosten & George, 2002). During withdrawal, this system becomes hypoactive, with a significant drop in dopamine levels in the NAc (Ozdemir et al., 2023). This dopamine deficit is believed to be the neurobiological substrate for the profound anhedonia, dysphoria, and lack of motivation that characterize the affective component of withdrawal (Kosten & George, 2002; Sarris et al., 2014). The functional disruption of this circuit shifts the motivation from seeking pleasure to seeking relief from the intensely negative emotional state of withdrawal (Vendruscolo & Koob, 2019).

**The Extended Amygdala and Stress Circuits:** The extended amygdala, including the central nucleus of the amygdala and the bed nucleus of the stria terminalis, is a key component of the brain's stress and fear circuitry (Vendruscolo & Koob, 2019). This system is activated during withdrawal, contributing to the negative affective symptoms of anxiety, irritability, and dysphoria (Ozdemir et al., 2023). The activation of stress-related neuropeptides like corticotropin-releasing factor (CRF) within this circuit plays a pivotal role in the negative reinforcement that drives continued drug use (Wand, 2008). The anxiety and fear experienced during withdrawal are phenomenologically similar to those seen in panic disorder and generalized anxiety disorder, suggesting a shared neurocircuitry of distress (Ranganathan & Beitman, 1998; Munir & Takov, 2021).

**The Periaqueductal Gray (PAG) and Pain Pathways:** The PAG is a critical brainstem region for the modulation of pain and is a primary site of action for the analgesic effects of opioids (King et al., 2005). Chronic opioid use induces neuroadaptive changes in this and other pain-modulating circuits. During withdrawal, these adaptations can lead to a state of opioid-induced hyperalgesia (OIH), a paradoxical increase in pain sensitivity (King et al., 2005; Bekhit, 2010). This phenomenon contributes to the diffuse muscle and bone pain that is a hallmark symptom of opioid withdrawal (Hosztafi, 2011), making patients more sensitive to pain than they were before opioid exposure (King et al., 2005; Gil Martín et al., 2014).

**The Hippocampus and Prefrontal Cortex (PFC):** These regions are crucial for memory and executive functions, respectively. Cognitive impairments, such as difficulty with concentration, memory, and decision-making, are common during both acute and protracted withdrawal (Dunn et al., 2023; Fava, 2003). While direct evidence from the provided sources is limited, it is plausible that the widespread neurochemical chaos of withdrawal—including dysregulation of norepinephrine, dopamine, and glutamate—disrupts the normal functioning of these higher-order cognitive circuits (Ruiz‐Rizzo & Lópera Restrepo, 2008; Kraus & Maki, 1998). Functional connectivity studies in depression, for example, show altered communication within and between networks like the default mode network and executive control network, which could serve as an analogue for the cognitive deficits seen in withdrawal (Chen & Gong, 2021).

### Neuroimaging Findings

The provided literature base does not include specific neuroimaging studies (e.g., fMRI, PET) conducted on human subjects during opioid withdrawal. However, the use of such techniques is essential for understanding brain function in vivo. Studies in related fields highlight their potential. For instance, neuroimaging in depression has revealed altered activity in limbic and prefrontal regions, correlating with symptoms like anhedonia and cognitive dysfunction (Chen & Gong, 2021; Sahakian & Morein‐Zamir, 2011). Similarly, imaging studies in patients with chronic pain demonstrate structural and functional changes in brain areas involved in pain processing (Ku-Lang Chang et al., 2015). It is reasonable to hypothesize that neuroimaging during opioid withdrawal would reveal hyperactivity in regions like the LC and amygdala, hypoactivity in the NAc and PFC, and altered connectivity across brain networks involved in emotion, arousal, and cognition. The mention of neuroimaging techniques like MRI and CT in various neurological contexts (e.g., Prajapati et al., 2024; Kunihiro et al., 2011; Westmoreland, 2001) underscores their critical role in modern neuroscience, and their application to opioid withdrawal represents a vital area for future research to objectively map the functional brain changes underlying the syndrome.

## Developmental Neurobiology

The neurobiological effects of opioid exposure and withdrawal are not uniform across the lifespan. The developing brain is uniquely vulnerable to the influence of exogenous substances, and exposure during critical periods of neurodevelopment can have profound and lasting consequences. The most dramatic example of this is Neonatal Abstinence Syndrome (NAS), a withdrawal syndrome in newborns exposed to opioids in utero. Furthermore, adolescence represents another period of significant neurodevelopmental change and heightened vulnerability to the initiation of substance use and the development of addiction.

### Neonatal Abstinence Syndrome (NAS)

NAS is a postnatal drug withdrawal syndrome that occurs in infants exposed to addictive substances, most commonly opioids, during pregnancy (Ko et al., 2017; Nargarathan et al., 2019). When a pregnant woman uses opioids, these substances cross the placenta, and the fetus develops physical dependence (Ledesma Serrano, 2019). After birth, the supply of the drug is abruptly cut off, precipitating a withdrawal syndrome in the neonate (Ko et al., 2017; Serrano, 2017).

The clinical presentation of NAS is a multisystem disorder reflecting CNS hyperexcitability and autonomic dysregulation (Nargarathan et al., 2019). Symptoms typically appear within 48-72 hours after birth and can include a high-pitched cry, irritability, tremors, hypertonia, and sleep disturbances (Ko et al., 2017; Nargarathan et al., 2019). Gastrointestinal dysfunction is also prominent, with symptoms such as poor feeding, regurgitation, vomiting, and loose stools (Ledesma Serrano, 2019; Nargarathan et al., 2019). Autonomic signs include fever, sweating, sneezing, and tachypnea (Ko et al., 2017). In severe cases, seizures can occur (Aktas et al., 2016). The constellation of symptoms is often summarized by the acronym WITHDRAWAL: Wakefulness, Irritability, Tremulousness/Temperature variation/Tachypnea, Hyperactivity/High-pitched cry, Diarrhea/Diaphoresis, Rub marks/Respiratory distress, Apneic attacks, Weight loss, Alkalosis, and Lacrimation (Unknown, 1983).

The neurobiological underpinnings of NAS mirror those of adult withdrawal, involving adaptations in the opioid, noradrenergic, and other neurotransmitter systems in the developing fetal brain (Ko et al., 2017). The abrupt cessation of opioid stimulation at birth leads to a state of neuronal hyperexcitability, manifesting as the clinical syndrome (Nargarathan et al., 2019). The management of NAS often requires both non-pharmacologic supportive care (e.g., swaddling, low-stimulation environment) and, in more severe cases, pharmacologic treatment to ameliorate withdrawal symptoms (Nargarathan et al., 2019). This typically involves replacing the opioid the infant was exposed to with a long-acting opioid like morphine or methadone, which is then slowly tapered (Nargarathan et al., 2019; Modebelu et al., 2019).

The long-term neurodevelopmental consequences of in utero opioid exposure and subsequent NAS are a significant concern. While not detailed extensively in the provided sources, conditions such as Fetal Alcohol Syndrome, which involves prenatal alcohol exposure, demonstrate that substance use during gestation can lead to lasting cognitive, behavioral, and physical deficits (Lewis & Woods, 1994; Coles, 2003). It is plausible that similar long-term effects on behavior, cognition, and stress regulation systems may occur following prenatal opioid exposure, representing a critical area for ongoing research.

### Adolescent Vulnerability

Adolescence is a critical neurodevelopmental period characterized by significant remodeling of brain circuits, particularly those involving the prefrontal cortex (PFC), which is responsible for executive functions like impulse control and decision-making, and the limbic system, which governs emotion and reward (Winters & Ingwalson, 2022). This developmental trajectory, where the reward-seeking limbic system matures earlier than the impulse-controlling PFC, creates a period of heightened vulnerability to risky behaviors, including the initiation of substance use (Schwartz, 1984; Winters & Ingwalson, 2022).

Adolescents who misuse psychoactive substances often exhibit characteristics such as boredom, restlessness, impulsiveness, and low frustration tolerance (Schwartz, 1984). These traits may be both a cause and a consequence of substance use. The adolescent brain is particularly sensitive to the rewarding effects of drugs, which can accelerate the transition from experimental use to addiction (Winters & Ingwalson, 2022). Factors such as peer pressure, a desire for novel experiences, and attempts to self-medicate underlying emotional problems like anxiety or depression can also contribute to substance use initiation (Batta & Farid, 2011; Winters & Ingwalson, 2022).

The neurobiological changes induced by chronic opioid use during this critical period may have more profound and lasting effects than when initiated in adulthood. Disruption of normal synaptic pruning and myelination processes in the PFC could lead to long-term deficits in executive function and impulse control, perpetuating the cycle of addiction (Winters & Ingwalson, 2022). Therefore, preventing opioid use in this vulnerable population is a key public health strategy, and treatments for adolescent opioid use disorder must be developmentally informed, addressing the unique psychosocial and neurobiological context of this age group (Schwartz, 1984).

## Treatment Mechanisms

The management of opioid withdrawal is a critical first step in the treatment of opioid use disorder, aiming to alleviate the severe physical and psychological distress of abstinence, prevent complications, and facilitate engagement in long-term recovery (Daley & Douaihy, 2006). Pharmacological interventions are the cornerstone of withdrawal management, targeting the underlying neurobiological disruptions that cause the syndrome (Kleber, 2007). These strategies primarily involve either replacing the illicit opioid with a medically supervised, long-acting opioid (agonist therapy) or mitigating the symptoms of withdrawal with non-opioid medications.

### Opioid Agonist and Partial Agonist Therapy

The most effective method for managing opioid withdrawal involves substituting the short-acting opioid of abuse (e.g., heroin) with a longer-acting, pharmacologically controlled opioid agonist, such as methadone, or a partial agonist, like buprenorphine (Kleber, 2007; Zoorob et al., 2018).

**Methadone:** Methadone is a full μ-opioid receptor agonist with a long half-life (Kleber, 2007; Komrowski & Sekhri, 2021). When administered in stable doses, it occupies opioid receptors, preventing the onset of withdrawal symptoms and reducing cravings without producing the intense euphoria associated with short-acting opioids like heroin (Kosten & George, 2002). By stabilizing the opioid system, methadone allows the patient to disengage from the cycle of intoxication and withdrawal, enabling them to focus on psychosocial rehabilitation (Kleber, 2007; Maremmani et al., 2010). After a period of stabilization, the methadone dose can be slowly tapered over weeks or months to achieve detoxification (Kleber, 2007; Thompson et al., 2021).

**Buprenorphine:** Buprenorphine is a partial agonist at the μ-opioid receptor and an antagonist at the κ-opioid receptor (Weibel et al., 2013; Zoorob et al., 2018). As a partial agonist, it has a "ceiling effect" on respiratory depression, making it safer in overdose compared to full agonists like methadone or heroin (Zoorob et al., 2018; Komrowski & Sekhri, 2021). It effectively alleviates withdrawal symptoms and cravings by providing a sufficient level of μ-opioid receptor stimulation (Kleber, 2007). Its high affinity for the μ-receptor also allows it to block the effects of other opioids if they are used concurrently (Kosten & George, 2002). Buprenorphine is often co-formulated with naloxone, an opioid antagonist, to deter intravenous misuse (Zoorob et al., 2018). Tapering buprenorphine is also a primary strategy for detoxification (Kleber, 2007; Thompson et al., 2021). Both methadone and buprenorphine-based detoxification and maintenance are considered the most effective treatments for opioid dependence, leading to better treatment retention and reduced illicit opioid use (Schuckit, 2016; Kleber, 2007).

### Opioid Antagonist Therapy

Opioid antagonists, such as naltrexone, work by blocking opioid receptors, thereby preventing exogenous opioids from producing their effects (Kleber, 2007). Naltrexone is used for relapse prevention rather than withdrawal management (O'Shea et al., 2009). A patient must be fully detoxified from opioids before starting naltrexone, as administering it to a physically dependent individual will precipitate a severe withdrawal syndrome (Kleber, 2007). While effective for highly motivated individuals, initiating naltrexone can be difficult (Schuckit, 2016). Naloxone is a short-acting antagonist used primarily for the emergency reversal of opioid overdose (Rastegar, 2020; Monotti, 1993).

### Non-Opioid Symptomatic Management

Several non-opioid medications are used to target specific neurobiological systems dysregulated during withdrawal.

**α2-Adrenergic Agonists:** As discussed previously, hyperactivity of the locus coeruleus (LC) is a major driver of autonomic withdrawal symptoms. α2-adrenergic agonists, such as clonidine and lofexidine, act as "opioid-sparing" agents by suppressing this noradrenergic surge (Kleber, 2007; Pergolizzi et al., 2018). They bind to α2-autoreceptors on LC neurons, reducing their firing rate and thereby mitigating symptoms like anxiety, agitation, muscle cramps, sweating, and diarrhea (Pergolizzi et al., 2018; Thompson et al., 2021). Lofexidine is structurally similar to clonidine but has a lower propensity to cause hypotension, a common dose-limiting side effect of clonidine (Pergolizzi et al., 2018). These agents are effective for managing many of the physical symptoms of withdrawal but are less effective for psychological symptoms like insomnia and craving (Kleber, 2007).

**Adjunctive Medications:** Other medications can be used to target specific symptoms. Benzodiazepines may be used cautiously for short-term management of severe anxiety, agitation, or insomnia, though their abuse potential requires careful consideration, especially in patients with polysubstance use disorders (Thompson et al., 2021; Wright, 2020). Antiemetics such as metoclopramide can be used to manage nausea and vomiting (Swegle & Logemann, 2006; Finegan et al., 2018), and non-steroidal anti-inflammatory drugs (NSAIDs) may help with muscle and bone pain (Ku-Lang Chang et al., 2015).

### Emerging and Novel Approaches

The search for more effective and safer treatments for opioid withdrawal is ongoing. The provided literature mentions cannabidiol (CBD) as a potential non-opioid medication for adjunctive management of withdrawal (Kudrich et al., 2021). CBD is a non-intoxicating component of the cannabis plant and is hypothesized to help with symptoms like anxiety, pain, and insomnia, which are prominent in the withdrawal syndrome (Kudrich et al., 2021). This represents a promising area for future research. Similarly, the role of ketamine, an NMDA receptor antagonist, has been explored for its rapid antidepressant effects and potential utility in pain and addiction (Andrade, 2017; Upadhyay et al., 2011), suggesting that modulation of the glutamatergic system remains a key therapeutic target.

Ultimately, successful management of opioid withdrawal involves a multimodal approach that combines evidence-based pharmacotherapy with robust psychosocial support, counseling, and long-term relapse prevention strategies (Mahato et al., 2021; Daley & Douaihy, 2006).

## Future Directions

While our understanding of the biological basis of opioid withdrawal has advanced significantly, numerous questions remain, and the current therapeutic armamentarium, though effective, is far from perfect. The provided literature highlights several areas where further research is critically needed to refine our models of withdrawal, identify novel therapeutic targets, and improve clinical outcomes for individuals with opioid use disorder.

A primary area for future investigation is the elucidation of the long-term neurobiological consequences of chronic opioid use and repeated withdrawal cycles. The concept of a protracted withdrawal syndrome, characterized by persistent affective and somatic symptoms for months or even years, is clinically recognized but poorly understood from a mechanistic standpoint (Hosztafi, 2011; Ghaffarinejad et al., 2012). Longitudinal neuroimaging studies are needed to track structural and functional brain changes over time in individuals recovering from opioid dependence. Such studies could identify the neural correlates of persistent symptoms like anhedonia, anxiety, and cognitive dysfunction (Fava, 2003; Ozdemir et al., 2023), potentially revealing targets for new interventions. The limited availability of such studies in the current source material underscores a significant gap in the field.

Further research into the genetic and molecular underpinnings of individual variability in withdrawal severity is also essential. Identifying specific genetic polymorphisms that confer risk for severe withdrawal or protracted symptoms could pave the way for personalized medicine approaches (Schuckit, 2016). This could involve genotyping patients to predict their response to different withdrawal management strategies or to identify those who might benefit from more intensive or prolonged treatment. The role of epigenetic modifications—changes in gene expression without alteration of the DNA sequence itself—is another promising frontier, as chronic drug exposure is known to induce lasting changes in the neuronal epigenome.

The exploration of novel pharmacological targets beyond the classic monoamine and opioid systems is crucial. The glutamatergic system, particularly the NMDA receptor, has been identified as a key player in withdrawal hyperexcitability (Rasmussen, 2002; Trujillo, 2012), but developing agents that can safely modulate this system in humans remains a challenge. The potential utility of cannabidiol (CBD) for ameliorating withdrawal-related anxiety, pain, and insomnia is an exciting avenue that warrants rigorous clinical trials (Kudrich et al., 2021). Similarly, investigating the role of the neuroimmune system, including microglial activation and pro-inflammatory cytokines, may yield new therapeutic strategies. The link between cytokines, stress, and depression is well-established in other contexts (Anisman et al., 2005; Anisman & Merali, 2003), and targeting neuroinflammation could potentially alleviate the malaise, pain, and negative affective components of opioid withdrawal.

Another critical direction is the development of treatments for specific, challenging aspects of the withdrawal syndrome. For instance, the cognitive deficits associated with withdrawal, such as impaired concentration and memory, significantly impact a patient's ability to engage in psychosocial therapy and reintegrate into daily life (Dunn et al., 2023). Research into cognitive-enhancing agents or targeted cognitive remediation therapies for this population is needed. Similarly, sleep disturbances are a persistent and distressing feature of both acute and protracted withdrawal that contributes to relapse (Hosztafi, 2011; Dunn et al., 2023). Developing effective, non-addictive treatments for withdrawal-related insomnia is a high priority (Pagel et al., 2018).

Finally, the phenomenon of opioid-induced hyperalgesia (OIH), a state of paradoxical pain sensitization, complicates both pain management and withdrawal (King et al., 2005; Bekhit, 2010). Future research must better differentiate the mechanisms of OIH from those of pharmacologic tolerance to develop strategies that can prevent or reverse it. This could involve the use of NMDA receptor antagonists or other non-opioid adjuncts that can preserve the analgesic efficacy of opioids while mitigating their pro-nociceptive effects (King et al., 2005; Gil Martín et al., 2014). Bridging the gap between preclinical animal models, where many of these mechanisms have been explored, and human clinical research is a fundamental challenge that must be overcome to translate basic science discoveries into effective clinical practice.

## Conclusion

Opioid withdrawal is a complex and clinically significant neuropsychiatric syndrome driven by profound neuroadaptations in the central nervous system. It represents far more than the mere absence of a drug; it is an active, hyper-excitable state resulting from the unmasking of homeostatic changes in multiple, interconnected neurobiological systems. The core of the syndrome lies in the brain's attempt to counteract the persistent inhibitory effects of chronic opioid administration, a process that involves both the endogenous opioid system and a host of non-opioid neurotransmitter pathways (Kosten & George, 2002; Koch et al., 2003).

The physical manifestations of withdrawal, including autonomic hyperactivity and somatic distress, are primarily driven by a surge in noradrenergic activity originating from a disinhibited locus coeruleus (Rasmussen, 2002). Concurrently, a state of glutamatergic hyperactivity, mediated by upregulated NMDA receptors, contributes to generalized neuronal excitability, pain amplification, and anxiety (Trujillo, 2012). The debilitating affective components of withdrawal—dysphoria, anhedonia, and intense craving—are linked to a dopamine deficit in the brain's reward pathways and the activation of stress circuits within the extended amygdala (Ozdemir et al., 2023; Wand, 2008). These biological events create a powerful negative reinforcement cycle, compelling the individual to relapse in order to alleviate the profound physical and emotional distress (Dunn et al., 2023; Vendruscolo & Koob, 2019).

The clinical presentation is further shaped by developmental factors, with the developing nervous system showing unique vulnerabilities, as exemplified by Neonatal Abstinence Syndrome (Ko et al., 2017). Genetic predispositions also play a crucial role in determining an individual's susceptibility to dependence and the severity of their withdrawal experience (Schuckit, 2016).

Current pharmacological treatments for opioid withdrawal are rationally designed to target these underlying neurobiological disruptions. Opioid agonist and partial agonist therapies, such as methadone and buprenorphine, work by stabilizing the opioid system, thereby preventing withdrawal and reducing cravings (Kleber, 2007). Non-opioid approaches, like the use of α2-adrenergic agonists, directly counteract the noradrenergic hyperexcitability that produces many of the physical symptoms (Pergolizzi et al., 2018).

In synthesizing the available evidence, it becomes clear that a comprehensive understanding of opioid withdrawal requires an integrative perspective. The symptoms of pain, anxiety, depression, and insomnia are not merely psychological reactions but are deeply rooted in the same neurobiological systems implicated in primary pain, mood, and anxiety disorders. Acknowledging this overlap is crucial for destigmatizing addiction and for developing more effective, mechanism-based treatments. While significant progress has been made, the persistence of protracted withdrawal symptoms and the challenge of relapse highlight the enduring nature of opioid-induced neuroplasticity. Future research aimed at reversing these long-term changes and developing novel, non-addictive therapies to manage withdrawal symptoms remains a critical priority in addressing the ongoing opioid crisis.

## References

1. Abdelsayed, S., Acevedo, R., & Clemow, L. (2017). Is sleep deprivation associated with behavioral changes in children and adolescents?. Evidence-Based Practice. https://doi.org/10.1097/01.ebp.0000541629.93211.cb
2. Abhishek, A., & Doherty, M. (2016). Placebo, nocebo, and contextual effects. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199668847.003.0027
3. Adam, H. M. (2020). Headache. Pediatric Care Online. https://doi.org/10.1542/aap.ppcqr.396077
4. Adams, K., & Jones, J. V. (1998). Trichotillomania: Its Classification and Treatment. TCA Journal. https://doi.org/10.1080/15564223.1998.12034514
5. Adi, Y., Ashcroft, D. M., Browne, K. D., Beech, A. R., Fry-Smith, A., & Hyde, C. (2002). Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technology Assessment. https://doi.org/10.3310/hta6280
6. Ahemad, M., Ahmad, P. M. F., & Shafaat, M. (2018). Effect of Dalak (Massage) in the Management of Sahar (Insomnia). https://doi.org/10.37591/rrjoush.v5i2.130
7. Ahmed, S., & Paul, S. P. (2019). A Diagnostic Conundrum: Acute Intermittent Porphyria Coexisting with Lumbar Prolapsed Intervertebral Disc. Journal of College of Physicians And Surgeons Pakistan. https://doi.org/10.29271/jcpsp.2019.12.1236
8. Aktaş, S., Hakkı, ©., Bir, N., İntrauterin, N., Maruziyeti, E., Karakurt, L. T., & Saygı, M. (2016). Unexpected Cause of Neonatal Seizure: In Utero Heroin Exposure. Gazi Medical Journal. https://doi.org/10.12996/gmj.2016.48
9. Al-Mashkur, N. M., Hansen, C. M., Perczynski, L., & Pankiewicz, M. (2020). Differential diagnoses of dissociative amnesia in a younger woman. Ugeskrift for Læger.
10. Albishri, S. B., Alotaibi, A. B., Alzoubaidi, F. M., & Elserafy, O. S. (2023). Flakka: “The Zombie Drug” A Medicolegal Concern: An Updated Review of α-Pyrrolidinopentiophenone. The Saudi Journal of Forensic Medicine and Sciences. https://doi.org/10.4103/sjfms.sjfms_7_23
11. Alfarossi, O. L., & Hutasoit, H. B. K. (2020). Gejala Psikotik pada Pasien dengan Epilepsi Tidak Terkontrol. Jurnal Medula.
12. Ali, A. A., Shaer, S. S. E., Gad, A. M., & Abu‐Elfotuh, K. (2017). [P1–606]: IMPACT OF PHYSICAL AND MENTAL ACTIVITIES VERSUS PROTEIN MALNUTRITION ASSOCIATED WITH SOCIAL ISOLATION DURING INDUCTION AND PROGRESSION OF ALZHEIMER's DISEASE IN RATS. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2017.06.622
13. Ali, A. P. D. W. D. A. (2024). NEUROPHYSIOLOGY OF SLEEP PARALYSIS. International Journal of Education and Social Science Research. https://doi.org/10.37500/ijessr.2024.7106
14. Ali, N., Rasheed, A., Tariq, I., Abdullah, F., Sarwar, A., Atta, R., & Qammer, Z. (2018). Adjunct Use of Low Dose Risperidone Verses Adjunct Use of Clonazepam with an SSRI in Treatment of Moderate to Severe Anxiety States; A Comparative Study. National Journal of Health Sciences. https://doi.org/10.21089/njhs.32.0051
15. Alvarez, M. R., García, R. G., & Silva, F. A. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas. Acta neurológica colombiana.
16. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
17. Amsterdam, J. V., Pierce, M., & Brink, W. V. D. (2023). Predictors and motives of polydrug use in opioid users. A narrative review. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000875
18. Anand, K., Willson, D. F., Berger, J., Harrison, R., Meert, K. L., Zimmerman, J. J., Carcillo, J. A., Newth, C. J. L., Prodhan, P., Dean, J. M., & Nicholson, C. (2010). Tolerance and Withdrawal From Prolonged Opioid Use in Critically Ill Children. PEDIATRICS. https://doi.org/10.1542/peds.2009-0489
19. Ananto, A. S., & Suryati, E. (2019). Ensefalopati Hipertensi pada Anak dengan Glomerulonefritis Akut Pasca Streptokokal.
20. Anari, A., Ghaffarinejad, A., & Sabzevari, L. (2012). P-66 - The prolonged syndrome of opium withdrawal. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)74233-5
21. Anderson, M. (2010). Benzodiazepines for prolonged seizures. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/adc.2009.176321
22. Andrade, C. (2017). Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17f11567
23. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). None. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s
24. Anisman, H., & Merali, Z. (2003). Cytokines, stress and depressive illness: brain‐immune interactions. Annals of Medicine. https://doi.org/10.1080/07853890310004075
25. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
26. Aptikieva, L. (2020). PSYCHOLOGICAL VIOLENCE CONSEQUENCES FOR DIFFERENT AGE CATEGORIES. Vestnik Orenburgskogo gosudarstvennogo universiteta. https://doi.org/10.25198/1814-6457-224-6
27. Arain, S., Shakhori, M. A., Thorakkattil, S. A., & Amin, O. (2023). Acute Psychotic Episode Induced by Antimicrobial Treatment. Case Reports in Psychiatry. https://doi.org/10.1155/2023/9996763
28. Arenson, C., Busby‐Whitehead, J., Brummel‐Smith, K., O’Brien, J. G., Palmer, M. H., & Reichel, W. (2010). Evaluation and Management of Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575952.017
29. Arnáez, S. (2019). Vulnerabilidad cognitiva a la hipocondría: intrusiones, valoraciones y creencias disfuncionales/ cognitive vulnerability to hypochondriasis: intrusions, appraisals and dysfunctional beliefs.
30. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
31. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
32. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
33. Artini, N. M. Y., & Adnyana, I. M. O. (2014). Penatalaksanaan Medication-overuse Headache. Cermin Dunia Kedokteran.
34. Athanasou, J. A. (2016). Substance Abuse. SensePublishers eBooks. https://doi.org/10.1007/978-94-6300-657-6_17
35. Attia, E., & Kostro, K. (2015). Pica. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp374
36. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
37. Avari, J., Yuen, G. S., AbdelMalak, B., Mahgoub, N., Kalayam, B., & Alexopoulos, G. S. (2014). Assessment and Management of Late-Life Depression. Psychiatric Annals. https://doi.org/10.3928/00485713-20140306-04
38. Ayoob, A., & Janakiram, C. (2021). Let's Focus on Frailty. Journal of Indian Association of Public Health Dentistry. https://doi.org/10.4103/jiaphd.jiaphd_93_21
39. Ayşe, H., Hakkı, ©., Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium?. Gazi Medical Journal. https://doi.org/10.12996/gmj.2017.45
40. B.R, R., & N.K.C, E. (2019). A review on pain and its signals modulation by body. IP International Journal of Comprehensive and Advanced Pharmacology. https://doi.org/10.18231/j.ijcaap.2019.018
41. Backer, W. D. (2006). Obstructive Sleep Apnea-Hypopnea Syndrome. KARGER eBooks. https://doi.org/10.1159/000093150
42. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
43. Balpande, V., Umate, R., & Waghmare, S. M. (2021). Case report on Schizophrenia with extra-pyramidal Syndrome. NVEO - NATURAL VOLATILES & ESSENTIAL OILS Journal | NVEO.
44. Balvir, K. S., Dhanvij, B., Telrandhe, S., & Wajgi, R. D. (2021). A Case Report on Management of Subdural Hematoma. NVEO - NATURAL VOLATILES & ESSENTIAL OILS Journal | NVEO.
45. Barolin, G. S. (1998). Rehabilitation hospitalism. International Journal of Rehabilitation Research. https://doi.org/10.1097/00004356-199806000-00008
46. Barreno, E. M., López, M. J. R., & Menéndez, M. J. C. (2003). Trastornos cognitivos y psicóticos en un caso de epilepsia temporal antes y después de la lobectomía.
47. Barré, M. (2013). Influence de la cognition sociale (Théorie de l'Esprit) sur la rémission fonctionnelle de la dépression et l'aptitude professionnelle.
48. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
49. Batta, A., & Farid, B. (2011). Addiction in Adolescents ---- A Current Trend.
50. Baumann, P., & Martin-Du, P. R. (2008). Sexual dysfunctions induced by antidepressants and antipsychotics.
51. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
52. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
53. Behrman, S., & Ebmeier, K. P. (2014). Can exercise prevent cognitive decline?. PubMed.
54. Bekhit, M. H. (2010). Opioid-Induced Hyperalgesia and Tolerance. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e3181ed83a0
55. Bermúdez, C. M., & Barrientos, M. P. S. (2011). Manejo Integral de un paciente con secuelas neuropsiquiátricas por consumo crónico de alcohol. REVISTA MÉDICAS UIS.
56. Bhatt, A., & Gill, A. (2016). Opiate addiction - current trends and treatment options. International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20161911
57. Biali, M. E., & Besson, M. (2020). [Why using antidepressants in chronic pain ? Practical prescription recommendations].. PubMed.
58. Bibi, E. S. D. M. (2021). AN OVERVIEW OF POST WAR SOCIAL PROBLEMS IN SYRIA. Pakistan Journal of International Affairs. https://doi.org/10.52337/pjia.v2i2.63
59. Bixquert, M. (2013). Treatment of irritable bowel syndrome with probiotics: growing evidence.. PubMed.
60. Bjorvatn, B., Jernelöv, S., & Pallesen, S. (2021). Insomnia – A Heterogenic Disorder Often Comorbid With Psychological and Somatic Disorders and Diseases: A Narrative Review With Focus on Diagnostic and Treatment Challenges. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2021.639198
61. Blanco, C., & Bernardi, S. (2014). Gambling Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg62
62. Blay, S. L. (2011). A Case of Major Depressive Disorder and Symptoms of Polycystic Ovary Syndrome Responding to Escitalopram. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01183
63. Bogan, R. (2008). Treatment Options for Insomnia-Pharmacodynamics of Zolpidem Extended-Release to Benefit Next-Day Performance. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.09.1916
64. Boggs, C. L., Ripple, M., Ali, Z., Brassell, M., Levine, B., Jufer‐Phipps, R., Doyon, S., & Fowler, D. R. (2013). Anaphylaxis After the Injection of Buprenorphine. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12161
65. Bolten, M., & Légeret, C. (2021). Interface entre pédopsychiatrie et pédiatrie – illustré par le concept bâlois du traitement interdisciplinaire des troubles fonctionnels de la défécation. Paediatrica Métabolisme/maladies rares. https://doi.org/10.35190/f2021.2.1
66. Borowski, M. (2013). Addiction as a Disease. European Researcher. https://doi.org/10.13187/er.2013.55.1945
67. Bostwick, J. R., & Demehri, A. (2017). Pills to Powder: An Updated Clinician's Reference for Crushable Psychotropics. Current psychiatry.
68. Bran, C. (2021). BURNOUT VERSUS WELL-BEING IN ORGANIZATIONS. Journal Plus Education.
69. Brasas, F. D. L. T., Domínguez, A. D., Domínguez, R. D., Montero, C. G., Díaz, L. M., Monge, M. P., Hernández, N. E., & Redondo, M. L. (2016). Dysthymia. The importance of an early diagnosis and an efficient treatment. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1479
70. Bremer, E., & Trotti, L. M. (2019). My Husband Tells Me I’m Lazy. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190671099.003.0027
71. Bril, S., Shoham, Y., & Marcus, J. S. (2011). The ‘Mystery’ of Opioid-Induced Diarrhea. Pain Research and Management. https://doi.org/10.1155/2011/309685
72. Broomfield, N. M., Wild, M. R., & Espie, C. A. (2008). Assessment and treatment of insomnia in later life. Oxford University Press eBooks. https://doi.org/10.1093/med:psych/9780198569459.003.0011
73. Brown, S. L. (2006). Deterioration. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00682.x
74. Browne, R. B. (2011). The Belle Browne Pain Scale.
75. Brădeanu, A. V., Pascu, L. S., Ungurianu, S., Tutunaru, D., Rebegea, L., Terpan, M., & Ciubară, A. (2019). The Effect of Behaviour in Patients Who Are Hospitalized and Suffer from Alcohol Withdrawal. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.70594/brain/v10.s2/5
76. BS, A. H., & BA, M. F. (2018). Glossary. https://doi.org/10.1002/9781119449737.gloss
77. BSc, P. L. G. R., & BSc, D. B. R. (2008). Glossary of Technical Terms. https://doi.org/10.1002/9781444302264.gloss
78. Bueno, B. B., Soares, V. S., & Oliveira, C. F. D. (2014). Patologias associadas à deficiências na síntese do grupo heme. Revista Científica da FHO|Uniararas. https://doi.org/10.55660/revfho.v2i2.101
79. Bullock, R., & Teasdale, G. (1990). ABC of major trauma. Head injuries--II.. BMJ. https://doi.org/10.1136/bmj.300.6739.1576
80. Burkhart, P. W. M. K. K. (2014). Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. Journal of Blood Disorders & Transfusion. https://doi.org/10.4172/2155-9864.1000195
81. Cabrejo-Mendoza, H. J., & Albornoz-Muñoz, D. P. (2023). Trastorno de Acumulación: A propósito de un caso. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v86i1.4469
82. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Post-Stroke Apathy: An Exploratory Longitudinal Study. Cerebrovascular Diseases. https://doi.org/10.1159/000350202
83. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Supplementary Material for: Post-Stroke Apathy: An Exploratory Longitudinal Study. Figshare. https://doi.org/10.6084/m9.figshare.5124829
84. Carlson, G. A., & Pataki, C. (2016). Disruptive Mood Dysregulation Disorder Among Children and Adolescents. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/appi.focus.20150039
85. Carr, B. I., Akkız, H., Guerra, V., Üsküdar, O., Kuran, S., Karaoğullarından, Ü., Tokmak, S., Ballı, T., Ülkü, A., Akçam, T., Delik, A., Benli, B. A., Doran, F., Yalçın, K., Altntaş, E., Özakyol, A., Yücesoy, M., Bahçeci, H. İ., Polat, K. Y., ... Tokat, Y. (2018). The patient burden of opioidinduced bowel dysfunction. Clinical Practice. https://doi.org/10.4172/clinical-practice.1000409
86. Carrera, M. A. V., Correa, S. M. V., Prado, M. M. C., & Granados, K. P. M. (2019). Manejo de intoxicación por opioides. RECIMUNDO. https://doi.org/10.26820/recimundo/3.(4).diciembre.2019.494-510
87. Casanova, Y. C., Torres, M. N., Ramírez, M. D. L., Ferrer, A. B., Calvo, R. N., & Ramos, I. J. (2021). Plan de cuidados de enfermería para paciente con deterioro de la movilidad.. Revista Sanitaria de Investigación.
88. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
89. Cassano, G. B., Toni, C., Petracca, A., Deltito, J., Benkert, O., Curtis, G., Hippius, H., Maier, W., Shera, D., & Klerman, G. L. (1994). Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology. https://doi.org/10.1016/0924-977x(94)90314-x
90. Cha, Y., Baloh, R. W., Cho, C., Magnusson, M., Song, J., Strupp, M., Wuyts, F. L., & Staab, J. P. (2020). Mal de débarquement syndrome diagnostic criteria: Consensus document of the Classification Committee of the Bárány Society. Journal of Vestibular Research. https://doi.org/10.3233/ves-200714
91. Chang, K.-L., Fillingim, R. B., Hurley, R. W., & Schmidt, S. (2015). Chronic pain management: pharmacotherapy for chronic pain.. PubMed.
92. Charlesworth, J., Ghosn, O., Hussain, N., Mahmoud, R., Goncalves, V., & Godbole, M. (2023). A case report of an unusual presentation of a patient with recurrent idiopathic catatonia. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100111
93. Charlton, S. R. (2020). Psychology and Black History Month in the United States. Eye on Psi Chi Magazine. https://doi.org/10.24839/2164-9812.eye24.4.18
94. Chen, Z., & Gong, Q. (2021). Resting-State Functional Connectivity in Unipolar Depression. Cambridge University Press eBooks. https://doi.org/10.1017/9781108623018.007
95. Cherian, K., Shinozuka, K., Tabaac, B. J., Arenas, A., Beutler, B. D., Evans, V. D., Fasano, C., & Muir, O. S. (2023). Psychedelic Therapy: A Primer for Primary Care Clinicians – Part V. Ibogaine. https://doi.org/10.31234/osf.io/v3f4w
96. Chowdhury, A. N., & Basu, S. (2002). 'Impulsive pica': a new diagnostic category?. PubMed.
97. Chung, S., Oh, K., Cho, K., & Hwang, I.-K. (2003). Antidepressant-Induced Somnambulism：A Case of Mirtazapine. Sleep Medicine and Psychophysiology.
98. Clark, K. (2021). Dysphagia, dyspepsia, and hiccups. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198821328.003.0052
99. Cohen, J. A., Mowchun, J. J., Lawson, V. H., & Robbins, N. M. (2016). A 19-Year-Old Male with Stiffness and Weakness After Waking. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190491901.003.0026
100. Cohen, P. R. (2018). Cephalexin-associated Achilles Tendonitis: Case Report and Review of Drug-induced Tendinopathy. Cureus. https://doi.org/10.7759/cureus.3783
101. Coles, C. D. (2003). Individuals Affected by Fetal Alcohol Spectrum Disorder (FASD) and Their Families: Prevention, Intervention and Support.
102. Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021). Clinical management of cannabis withdrawal. Addiction. https://doi.org/10.1111/add.15743
103. Consoli, A., Carvalho, W. D., & Cohen, D. (2013). Side Effects of ECT. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199937899.003.0008
104. Cornett, E. M., Rando, L., Labbé, A. M., Perkins, W., Kaye, A. M., Kaye, A. D., Viswanath, O., & Urits, I. (2021). Brexanolone to Treat Postpartum Depression in Adult Women.. PubMed.
105. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
106. Correia‐Melo, F. S., Silva, S. S., Araújo-de-Freitas, L., & Quarantini, L. C. (2017). S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression. Brazilian Journal of Psychiatry. https://doi.org/10.1590/1516-4446-2016-2070
107. Correll, C. U., Yu, X., Xiang, Y., Kane, J. M., & Masand, P. S. (2017). Biological treatment of Acute Agitation Or Aggression with Schizophrenia Or Bipolar Disorder in the Inpatient Setting. Annals of Clinical Psychiatry. https://doi.org/10.1177/104012371702900203
108. Corruble, E., Warot, D., & Soubrie, C. (2003). Insomnia linked to medications. SLEEP. https://doi.org/10.1007/978-1-4615-0217-3_20
109. Costa, G. (2012). [Stress of driving: general overview].. PubMed.
110. Couto, F. S. D., & Mendonça, A. D. (2010). Sintomas psiquiátricos e comportamentais da demência. Revista Portuguesa de Clínica Geral. https://doi.org/10.32385/rpmgf.v26i1.10713
111. Creado, S., Plante, D., & Casey, K. R. (2017). 1220 Veteran with Sleep Eating, Post-traumatic Stress Disorder and Severe Obstructive Sleep Apnea. SLEEP. https://doi.org/10.1093/sleepj/zsx052.010
112. Cristancho, P., Cristancho, M. A., & Thase, M. E. (2010). Mood Stabilizing Medications. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0556
113. Cruz, M. C. D., Camargo, R. P. D., Cruz, L. C. D., Schiefelbein, N., Cruz, D. M. D., & Cruz, M. C. C. D. (2020). Migrânea: revisão de literatura. ARCHIVES OF HEALTH INVESTIGATION. https://doi.org/10.21270/archi.v10i2.4670
114. Daley, D. C., & Douaihy, A. (2006). The Recovery Process for Addiction and Mood Disorders. https://doi.org/10.1093/oso/9780195311297.003.0004
115. Dange, V., & Biswas, D. (2021). A Brief Review on Postpartum Depression. Journal of Pharmaceutical Research International. https://doi.org/10.9734/jpri/2021/v33i60b34924
116. Dashinie, S., & Renganathan, S. (2014). Major Depressive Disorder without Psychotic Features- A Case Report.
117. Dato, V., Campagnolo, E. R., Shah, D., Bellush, M. J., & Rupprecht, C. E. (2014). Recurrent Temporary Paralysis Reported After Human Rabies Post‐Exposure Prophylaxis. Zoonoses and Public Health. https://doi.org/10.1111/zph.12143
118. David, G., Monge, M. P., Arántzazu, D., Fernanda, A., Fernanda, T. M., Gemma, M., & Sandra, D. (2016). Schizophrenia and sexual desinhibition. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2162
119. Davies, D. (2023). Defining Alcoholism. Routledge eBooks. https://doi.org/10.4324/9781032616988-5
120. Debnath, M. (2021). A Case Report of Non-Reactive Psychosis in a COVID-19 Patient. RECENT ADVANCES IN PATHOLOGY AND LABORATORY MEDICINE. https://doi.org/10.24321/2454.8642.202104
121. Deng, S., Sheng, H.-Z., Zhou, Y., & Zhang, J. (2019). Whether we could forget pain or not after the scar healed? A discussion about changing the acute pain into chronic pain. Pain Clin J. https://doi.org/10.3760/cma.j.issn.1672-9633.2019.05.003
122. Deptola, S., Hemmann, B., Hemmelgarn, T., DiPaola, K., & Cortezzo, D. E. (2023). Propofol Sedation Washouts in Critically Ill Infants: A Case Series. The Journal of Pediatric Pharmacology and Therapeutics. https://doi.org/10.5863/1551-6776-28.4.354
123. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
124. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
125. Dillard, M., Bendfeldt, F., & Jernigan, P. (1993). Use of Thioridazine in Post-Traumatic Stress Disorder. Southern Medical Journal. https://doi.org/10.1097/00007611-199311000-00022
126. Doloka, Y. V., Drozdova, L. P., Khelimskii, A. M., Gnatyshev, L. V., Kuzennaya, S. C., & Romanyukha, R. V. (2016). [Epileptic seizures in servicemen].. PubMed.
127. Domenech, I. N., & Jiménez, M. G. (2020). MARCHIAFAVA-BIGNAMI: UNA GRAN DESCONOCIDA. A PROPÓSITO DE UN CASO. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p107
128. Domínguez, M. R., Burgos, L. M., & Bergink, V. (2020). Perinatal Mood and Anxiety Disorders. Obstetrics and gynecology.. https://doi.org/10.1002/9781119450047.ch16
129. Doran, K., & Halm, M. A. (2010). Integrating Acupressure to Alleviate Postoperative Nausea and Vomiting. American Journal of Critical Care. https://doi.org/10.4037/ajcc2010900
130. Dorn, S. D., Lembo, A., & Cremonini, F. (2014). Opioid-Induced Bowel Dysfunction: Epidemiology, Pathophysiology, Diagnosis and Initial Therapeutic Approach. The American Journal of Gastroenterology Supplements. https://doi.org/10.1038/ajgsup.2014.7
131. Drew, D., & Marie, B. S. (2011). Pain in Critically Ill Patients With Substance Use Disorder or Long-term Opioid Use for Chronic Pain. AACN Advanced Critical Care. https://doi.org/10.1097/nci.0b013e318220c504
132. Drew, D., & Marie, B. S. (2011). Pain in Critically Ill Patients With Substance Use Disorder or Long-term Opioid Use for Chronic Pain. AACN Advanced Critical Care. https://doi.org/10.4037/nci.0b013e318220c504
133. Duan, J., Huang, W., Zhou, M., Li, X., & Cai, W. (2013). Case report of adjunctive use of olanzapine with an antidepressant to treat sleep paralysis.. PubMed. https://doi.org/10.3969/j.issn.1002-0829.2013.05.010
134. Dubey, D., Misra, U. K., & Kalita, J. (2017). Status epilepticus: Refractory and super-refractory. Neurology India. https://doi.org/10.4103/neuroindia.ni_958_16
135. Duma, S., & Fung, V. S. (2019). Drug-induced movement disorders. Australian Prescriber. https://doi.org/10.18773/austprescr.2019.014
136. Dunn, K. E., Bergeria, C. L., Ware, O. D., & Strain, E. C. (2023). The Opioid Withdrawal Syndrome. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780197618431.013.8
137. Durst, P., Palazzolo, J., Peyrelong, J.-P., Berger, M., Chalabreysse, M., Billiard, M., & Vialle, A. (2005). Méthadone et Syndrome d'Apnées du Sommeil. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674370505000304
138. Durán, L. V. B., González, M., & Álvarez, G. B. (2020). Trastorno por estrés postrauma. Revista Medica Sinergia. https://doi.org/10.31434/rms.v5i9.568
139. Dydyk, A. M., Jain, N., & Gupta, M. (2021). Opioid Use Disorder.
140. Easterling, S., Master, V. A., & Carney, K. J. (2014). Evaluation and management of patients with nocturia. JAAPA. https://doi.org/10.1097/01.jaa.0000442703.33717.85
141. Edge, R., & Argáez, C. (2021). Droperidol for Agitation in Acute Care [Internet].
142. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
143. Elhassan, N. M., Al‐Salihy, Z., Bushra, M., Sanabel, A.-A., Albobaly, Y., Eltorki, Y., & Alabdulla, M. (2018). Use of Benzodiazepines and Hypnotic Medications in Psychiatry Older Adult Outpatients. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2018-11-1006
144. Elikowski, W., Małek‐Elikowska, M., Fertała, N., & Zawodna-Marszałek, M. (2021). Amiodarone-induced musical hallucinations.. PubMed.
145. Enrique, P. M. L., Gloria, A. S., Efraín, S. C. J., & Luis, G. A. J. (2019). Latencia diagnóstica en la enfermedad de Parkinson y su relación con los síntomas prodrómicos motores y no motores. eNeurobiología.
146. Escalante, M. L., Merejildo, W. P., Contreras, V. S., & Barroso, C. I. (2016). Cefalea hipnica secundaria a malformación arteriovenosa cerebral.
147. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
148. Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2006). Trastorno perceptivo persistente por alucinógenos después del consumo de psilocibina: un estudio clínico. European psychiatry (Ed Española). https://doi.org/10.1017/s1134066500003738
149. Evers, M. M., & Marin, D. B. (2002). Mood disorders. Effective management of major depressive disorder in the geriatric patient.. PubMed.
150. Fabrazzo, M., Fuschillo, A., Perris, F., & Catapano, F. (2019). The unmasking of hidden severe hyponatremia after long-term combination therapy in exacerbated bipolar patients. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000265
151. Fama, J. M., & Wilhelm, S. (2010). Obsessions. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0616
152. Farooq, N. S. M. U., Alex, A., & Matthews, R. (2016). Opioid Medications: Psychiatric Diagnosis. Journal of Addiction Research & Therapy.
153. Fasesan, O., & Alakeji, I. (2023). Catatonia in Renal Failure and Major Depressive Disorder: A Case Series. Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria). https://doi.org/10.30442/ahr.0903-10-212
154. Fasmer, O. B., & Øedegaard, K. J. (2002). Are Migraines and Bipolar Disorder Related.
155. Fava, M. (2003). Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment.. PubMed.
156. Feder, H. M., & Wormser, G. P. (2021). Studying College Students for the Development of Infectious Mononucleosis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab075
157. Ferreira, M. D. C., Varanda, S., Carneiro, G., Santos, B. H. D., & Machado, Á. (2016). Parkinson disease psychosis – A case report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.258
158. Ferrández, J. S.-R., Martín, A. G., Garcia, M. M., & García, T. M. (2014). Hiperalgesia asociada al tratamiento con opioides. Revista de la Sociedad Española del Dolor. https://doi.org/10.4321/s1134-80462014000500005
159. Fessas, P., & Duret, A. (2018). Question 1: Is there a role for the ketogenic diet in refractory status epilepticus?. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2018-315755
160. Fine, L., Dubrovsky, B., & Spielman, A. J. (2011). Insomnia. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805153311101010137
161. Finegan, W. C., McGurk, A., O’Donnell, W., Pederson, J., & Rogerson, E. (2018). Nausea and vomiting. CRC Press eBooks. https://doi.org/10.4324/9781315378527-41
162. Fingerhood, M. (2020). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0005
163. Fink, M. (2010). Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0011
164. Fischer, T., Agar, M., Hosie, A., & Teodorczuk, A. (2020). Unpacking agitation in practice: a call for greater precision. Age and Ageing. https://doi.org/10.1093/ageing/afaa110
165. Fisher, A. D., Bandini, E., Casale, H., & Maggi, M. (2011). Paraphilic Disorders: Diagnosis and Treatment. https://doi.org/10.1002/9781119963820.ch8
166. Foroutan, H. R., Vadiee, I., Nabavizadeh, A., Rafiee, M., Imanieh, M. H., Asadipouya, A., & Pirastehfar, M. (2005). CIDP and Achalasia: Two manifestations of a Disease or Coincidental Association. Iranian journal of medical sciences.
167. Fosburg, M., Crone, R. K., & Vitez, T. S. (1984). Nitrous Oxide Analgesia for Refractory Pain in the Terminally Ill. Survey of Anesthesiology. https://doi.org/10.1097/00132586-198406000-00098
168. Fox, C., Jimoh, F. O., & Cross, J. (2018). Intervention to prevent, delay or reduce frailty in community-living older adults..
169. Franklin, J. (1995). Addiction Medicine. JAMA. https://doi.org/10.1001/jama.1995.03520450026012
170. Frean, J., Jong, G. D., & Albrecht, R. (2008). Imaginary bugs, real distress: delusional parasitosis.. PubMed.
171. Frey, R., Winkler, D., Naderi‐Heiden, A., Strnad, S., Pjrek, E., Scharfetter, J., & Kasper, S. (2011). JS02-01 - Psychiatric intensive care. European Psychiatry. https://doi.org/10.1016/s0924-9338(11)73702-6
172. Fried, I., Fahoum, F., Frew, A. J., Andelman, F., Andelman‐Gur, M. M., & Salamon, N. (2021). Laser ablation of human guilt. Brain stimulation. https://doi.org/10.1016/j.brs.2021.11.020
173. Fujita, M., & Tsuruta, R. (2013). Pathophysiology and prevention of delayed neurological sequelae in carbon monoxide poisoning. Journal of the Japanese Society of Intensive Care Medicine. https://doi.org/10.3918/jsicm.20.373
174. Galanter, M. (2014). Network Therapy for Substance Use Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg60
175. Gallegos, A. P., & Aguilar, C. (2024). Síndrome de Abstinencia y Delirum Secundario al Uso de Opioides y Benzodiacepinas: Revisión Narrativa de la Literatura. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v8i1.10500
176. Ganda, K. M. (2013). Psychiatric Conditions: Assessment of Disease States and Associated Dental Management Guidelines. https://doi.org/10.1002/9781119421450.ch52
177. Garcia, M. O., Garnica, M. M., Marin, S. G., Martínez, C., Martínez, R. G., & Valle, P. B. D. (2017). A child with Pica. A case presentation. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.472
178. García, M. D. S., & Calderón, R. M. (2010). Síntomas no motores en la enfermedad de Parkinson y estimulación cerebral profunda. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009745
179. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
180. Garcı́a-Borreguero, D., Schwarz, C., Larrosa, O., Llave, Y. D. L., & Yébenes, J. G. D. (2003). <scp>l</scp> -DOPA–induced excessive daytime sleepiness in PD. Neurology. https://doi.org/10.1212/wnl.61.7.1008
181. Glance, J., Gopalan, P., & Ackerman, K. D. (2015). Substance Intoxication and Withdrawal States in the General Medical Setting. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199329311.003.0016
182. Glass, R. M. (1990). Blue mood, blackened lungs. Depression and smoking. JAMA. https://doi.org/10.1001/jama.264.12.1583
183. Glass, R. M. (1990). Blue mood, blackened lungs. Depression and smoking.. PubMed.
184. Goldenberg, F. (2003). Other medications used for insomnia. SLEEP. https://doi.org/10.1007/978-1-4615-0217-3_22
185. González, M. F. A. (2019). DETERMINACIÓN DE LOS EFECTOS FISIOLÓGICOS CAUSADOS POR ESTRÉS ACADÉMICO Y LABORAL EN ESTUDIANTES DE QUÍMICA Y QUÍMICO FARMACÉUTICO BIOLÓGO.
186. González, R. M., Quesada, H. S., & Sancho, L. V. (2010). Episodio mixto secundario al uso de fluoxetina en una paciente con un transtorno afectivo bipolar no diagnosticado. Revista Médica de Costa Rica y Centroamérica.
187. Graddy, R., & Rastegar, D. A. (2020). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0008
188. Grannell, L. (2020). Drug interaction resources: mind the gaps. Australian Prescriber. https://doi.org/10.18773/austprescr.2020.005
189. Gray, A. (2003). Quality use of medicines: The patient with Acute Cough. South African Family Practice. https://doi.org/10.4102/safp.v45i8.1896
190. Gupta, R., Singh, A. P., Mittal, A., & Chaturvedi, S. K. (2024). "FROM BOOST TO BREAKDOWN "PERFORMANCE ENHANCEMENT AND THE DARK SIDE OF MEPHENTERMINE ADDICTION” A CASE SERIES. Global Journal For Research Analysis. https://doi.org/10.36106/gjra/0506138
191. Gupta, S., Laddha, A., Chaturvedi, P., Chaturvedi, N., Mishra, A., & Raghvendra, R. (2011). Trends and strategy towards therapies for status epilepticus: A decisive review. International Journal of Pharmaceutical Sciences Review and Research.
192. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
193. Guszkowska, M. (2013). [Exercise dependence--symptoms and mechanisms].. PubMed.
194. Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020). The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320967183
195. Gómez‐Revuelta, M., Blanco, L. S., Ruíz, M. J., Jenaro, G. P. D. S., Rodríguez, R. L., Olivares, O. P., & Morales, N. N. (2017). A Clinical review about differential diagnosis and comorbidities on premenstrual dysphoric disorder. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.577
196. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
197. Gürel, A. (2016). Multisystem toxicity after methamphetamine use. Clinical Case Reports. https://doi.org/10.1002/ccr3.487
198. Hainline, B., Gurin, L., & Torres, D. M. (2019). Concussion Two Weeks Later. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0007
199. Hainline, B., Gurin, L., & Torres, D. M. (2019). Multiple Concussions and Retirement from Sport. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0028
200. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
201. Hansson, E. E., Månsson, N.-O., & Håkansson, A. (2005). Assessment and management of vertigo and dizziness among older persons. Reviews in Clinical Gerontology. https://doi.org/10.1017/s0959259805001565
202. Hao, Y., Controzzi, M., Cipriani, C., Popović, D. B., Yang, X., Chen, W., Zheng, X., & Carrozza, M. C. (2013). Controlling hand-assistive devices: utilizing electrooculography as a substitute for vision. IEEE Robotics & Automation Magazine. https://doi.org/10.1109/mra.2012.2229949
203. Haro, G. (2012). New Clinical Implications of Opiate Maintenance Treatments. international journal high risk behaviors & addiction. https://doi.org/10.5812/ijhrba.6532
204. Hart, G. R. (1981). Withdrawal syndromes and the cessation of antihypertensive therapy. Archives of Internal Medicine. https://doi.org/10.1001/archinte.141.9.1125
205. Hart, G. R., & Anderson, R. J. (1981). Withdrawal syndromes and the cessation of antihypertensive therapy.. PubMed.
206. Harten, P. N. V., Hoek, H. W., & Kahn, R. S. (1999). Fortnightly review: Acute dystonia induced by drug treatment. BMJ. https://doi.org/10.1136/bmj.319.7210.623
207. Hautzinger, M. (1993). Depressionen. Verhaltenstherapie. https://doi.org/10.1007/978-3-662-22591-2_63
208. Hawkes, M. A., & Hocker, S. E. (2021). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0057
209. Hernández, G., García, L. H., Baez, I. C., Rodrigo, A. M., Torres, C. D., Gómez-Juanes, R., & Pérez, P. G. (2023). Antiandrogenic treatment of obsessive compulsive neurosis: A case review. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1961
210. Hernández, Y. D. C. S. (2016). Alteraciones estructurales de las regiones cerebrales sexuales tras empleo de paroxetina versus agomelatina. https://doi.org/10.14201/gredos.129703
211. Hertz, L., Song, D., Li, B., Du, T., Xu, J., Gu, L., Chen, Y., & Liang, P. (2014). Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. Journal of Signal Transduction. https://doi.org/10.1155/2014/593934
212. Hill, K. (2021). A fear of dogs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0011
213. Hillman, D. R., Carlucci, M., Charchaflieh, J., Cloward, T. V., Gali, B., Gay, P. C., Lyons, M. M., McNeill, M. M., Singh, M., Yılmaz, M., & Auckley, D. (2023). Society of Anesthesia and Sleep Medicine Position Paper on Patient Sleep During Hospitalization. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000006395
214. Hirschfeld, R. M. A., Calabrese, J. R., Frye, M. A., Lavori, P. W., Sachs, G., Thase, M. E., & Wagner, K. D. (2007). Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.. PubMed.
215. Hocker, S. E., Wijdicks, E. F. M., & Rabinstein, A. A. (2013). Refractory status epilepticus: new insights in presentation, treatment, and outcome. Neurological Research. https://doi.org/10.1179/1743132812y.0000000128
216. Hoell, I., Amanzada, A., Degner, D., & Havemann‐Reinecke, U. (2011). [Pregnant opioid addicted patients and additional drug intake. Part II: Comorbidity and their therapy].. PubMed.
217. Hong, I. S., & Bishop, J. R. (2014). Geriatric Patients: Choose Wisely: Age-Related Physiologic Changes, Risk of Adverse Effects Guide Your Prescribing. Current psychiatry.
218. Hong, S. I., Cho, D. H., Kang, H., Chung, D. J., & Chung, M. Y. (2006). Acute Onset of Steroid Psychosis with Very Low Dose of Prednisolone in Sheehan's Syndrome. Endocrine Journal. https://doi.org/10.1507/endocrj.53.255
219. Hosztafi, S. (2011). [Heroin addiction].. PubMed.
220. Huprich, S. K. (2010). Schizoid Personality Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0819
221. Hybels, C. F., Blazer, D. G., & Steffens, D. C. (2006). Partial remission. A common outcome in older adults treated for major depression.. PubMed.
222. Ikeda, A. (2016). I. How to Make a Diagnosis of Epilepsy and Its Classification. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.105.1348
223. Ilbeigi, M. S., Davidson, M., & Yarmush, J. (1998). An Unexpected Arousal Effect of Etomidate in a Patient on High-dose Steroids . Anesthesiology. https://doi.org/10.1097/00000542-199812000-00045
224. Ingrassia, G. F. (2012). HISTORICAL EVOLUTION OF MEDICAL KNOWLEDGE IN THE FIELD OF VEGETATIVE STATE.
225. Iorga, M., Stârcea, I. M., Munteanu, M., & Sztankovszky, L.-Z. (2014). PSYCHOLOGICAL AND SOCIAL PROBLEMS OF CHILDREN WITH CHRONIC KIDNEY DISEASE.
226. Issa, B. A. (2013). Prevalence and Correlates of Depressive Disorders among People Living with HIV/AIDS, in North Central Nigeria. Journal of AIDS & Clinical Research. https://doi.org/10.4172/2155-6113.1000251
227. Jahan, A. R., & Burgess, D. M. (2021). Substance Use Disorder. StatPearls.
228. Jang, W. I., Kim, Y. S., Kim, D. W., & Lee, B. D. (2010). A Case of Bilateral Sudden Sensorineural Hearing Loss Occurring after Taking the Aspirin. Journal of Clinical Otolaryngology Head and Neck Surgery. https://doi.org/10.35420/jcohns.2010.21.1.67
229. Jaspal, H., Neupane, D., & Madhusoodanan, S. (2019). Coprophagia in an older adult with Schizophrenia- A case report and brief review. Medical Case reports and Reviews. https://doi.org/10.15761/mcrr.1000135
230. Jay, G. W. (2013). Interdisciplinary Treatment of Chronic Noncancer Pain. CRC Press eBooks. https://doi.org/10.3109/9781439824894-12
231. Jiménez, C., & Belén, M. (2019). Terapia de aceptación y compromiso grupal aplicada a pacientes adictos a los opioides con el manejo de los síntomas de abstinencia junto con la terapia farmacológica para evitar recaídas a futuro.
232. Jones, A. L. (2016). Management of opioid poisoning. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199600830.003.0319
233. Kaggwa, M. M., Nkola, R., Najjuka, S. M., Bongomin, F., Ashaba, S., & Mamun, M. A. (2021). Extrapyramidal Side Effects in a Patient with Alcohol Withdrawal Symptoms: A Reflection of Quality of the Mental Health Care System. Risk Management and Healthcare Policy. https://doi.org/10.2147/rmhp.s314451
234. Kahn, D., & Chaplan, R. (2002). The “Good Enough” Mood Stabilizer: A Review of the Clinical Evidence. CNS Spectrums. https://doi.org/10.1017/s1092852900017594
235. Kap, Y. S. (2010). A Primate View on Multiple Sclerosis.
236. Karakatsoulis, G. N., Tsapakis, E.-M., & Fountoulakis, K. Ν. (2021). Clinical characteristics and treatment of treatment-resistant bipolar depression. Psychiatriki. https://doi.org/10.22365/jpsych.2021.048
237. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication]..
238. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication].. PubMed.
239. Katzman, M. A. (2021). The Diagnosis of Major Depressive Disorder is based on the Person's Reported Experiences and a Mental Status Examination. Journal of Aging and Geriatric Medicine.
240. Kennedy, J. E., Jaffee, M. S., & Cooper, D. (2013). Posttraumatic Stress Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da08
241. Ketch, T., Biaggioni, I., Robertson, R. M., & Robertson, D. (2002). Four Faces of Baroreflex Failure. Circulation. https://doi.org/10.1161/01.cir.0000017186.52382.f4
242. Kheifets, M. (2020). DRESS Syndrome-An Unusual Presentation with Pancytopenia after Salazopyrin Treatment. American Journal of Biomedical Science & Research. https://doi.org/10.34297/ajbsr.2020.07.001144
243. Kim, G. S., Nunez, T., & Vargas, E. (2021). Omeprazole-induced Visual Hallucinations: A Case Report. Journal of Psychiatric Practice. https://doi.org/10.1097/pra.0000000000000575
244. Kim, G.-M., Jeong, W., & Hwang, T. (2019). Depression and Gap between Perceived- and Self-Willingness-to-Pay for Labor in Community-Dwelling Full-Time Female Homemakers. Journal of Korean Neuropsychiatric Association. https://doi.org/10.4306/jknpa.2019.58.4.322
245. Kim, H. A., Bisdorff, A., Bronstein, A. M., Lempert, T., Rossi-Izquierdo, M., Staab, J. P., Strupp, M., & Kim, J. (2019). Hemodynamic orthostatic dizziness/vertigo: Diagnostic criteria. Journal of Vestibular Research. https://doi.org/10.3233/ves-190655
246. KIMURA, Y., KINEBUCHI, A., Kurokawa, T., SHIMIZU, T., Tanada, R., Inaki, K., & Satō, H. (2008). Yokukansan-based Prescriptions for Care Providers with Various Symptoms. Kampo Medicine. https://doi.org/10.3937/kampomed.59.499
247. King, S. A. (2003). Chronic Pain Control: What's Adequate- and Appropriate?.
248. King, T., Ossipov, M. H., Vanderah, T. W., Porreca, F., & Lai, J. (2005). Is Paradoxical Pain Induced by Sustained Opioid Exposure an Underlying Mechanism of Opioid Antinociceptive Tolerance?. Neurosignals. https://doi.org/10.1159/000087658
249. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2007.9.2/hkleber
250. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options.. PubMed.
251. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
252. Koch, T., Schulz, S., & Höllt, V. (2003). Different Intracellular Signaling Systems Involved in Opioid Tolerance/Dependence. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_4
253. Kocsis, J. H., & Brody, B. D. (2013). Chronic depression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175869.010
254. Kolla, B., & Hocker, S. E. (2021). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0045
255. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4.473
256. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4_part_2.473
257. Komrowski, M. D., & Sekhri, N. (2021). A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain. Journal of Opioid Management. https://doi.org/10.5055/jom.2021.0641
258. Koo, B., Kim, Y.-K., Cho, S.-H., & Kim, Y.-I. (2013). Male Chronic Pelvic Pain Syndrome. Soonchunhyang Medical Science. https://doi.org/10.15746/sms.13.036
259. Kosten, T., & George, T. P. (2002). The Neurobiology of Opioid Dependence: Implications for Treatment. Science & Practice Perspectives. https://doi.org/10.1151/spp021113
260. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
261. Kraus, M. F., & Maki, P. M. (1998). Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review. Journal of Head Trauma Rehabilitation. https://doi.org/10.1097/00001199-199804000-00014
262. Krawczyk, M., Thiel, A., Jüngst, C., & Lammert, F. (2018). Peculiar cases of ibuprofen-induced acute liver failure with distinct outcomes. Zeitschrift für Gastroenterologie. https://doi.org/10.1055/s-0037-1612729
263. Krawitz, R., & Watson, C. (2003). Prescribing in the acute situation. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198520672.003.0016
264. Krystal, A. D. (2005). The Effect of Insomnia Definitions, Terminology, and Classifications on Clinical Practice. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2005.53391.x
265. Kudrich, C., Hurd, Y. L., Salsitz, E. A., & Wang, A. (2021). Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol. Cannabis and Cannabinoid Research. https://doi.org/10.1089/can.2021.0089
266. KuKanich, B., & Wiese, A. J. (2015). Opioids. https://doi.org/10.1002/9781119421375.ch11
267. Kumar, N., Mendonça, D. A., & Jog, M. (2017). Teaching Video Neuro <i>Images:</i> Lithium-induced reversible Pisa syndrome. Neurology. https://doi.org/10.1212/wnl.0000000000003892
268. Kumari, D., & Kumar, P. (2023). Psychosocial Functioning of Females with Chronic Anxiety Disorder. Journal of Psychosocial Well-being. https://doi.org/10.55242/jpsw.2023.4107
269. Kunihiro, T., Soma, K., & Nakai, K. (2011). Cerebrospinal fluid leakage in a patient with depression: pre-existing depression may complicate the clinical picture of this complex syndrome. Equilibrium Research. https://doi.org/10.3757/jser.70.489
270. Kuzminov, V. (2019). he dependence of the clinical picture of acute psychosis connected with alcohol withdrawal from the forms of alcohol consumption. Ukrains kyi Visnyk Psykhonevrolohii. https://doi.org/10.36927/2079-0325-v27-is1-2019-16
271. Kułakowska, A., Pogorzelski, R., Borowik, H., & Drozdowski, W. (2003). Wearing off phenomenon presenting with features of paroxysmal abdominal pain.
272. Laliberte, B., & Kishk, O. A. (2017). Serotonin Syndrome in a Pediatric Patient After Vilazodone Ingestion. Pediatric Emergency Care. https://doi.org/10.1097/pec.0000000000001115
273. Lammers, M., & Ahmed, A. (2013). Melatonin for Sundown Syndrome and Delirium in Dementia: Is It Effective?. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12296
274. Lasocka, M., Konopko, M., Basińska-Szafrańska, A., Rogowski, A., & Sienkiewicz‐Jarosz, H. (2020). Seizures in alcohol withdrawal syndrome. Aktualności Neurologiczne. https://doi.org/10.15557/an.2020.0008
275. Lavigne, G., Babiloni, A. H., Beetz, G., Fabbro, C. D., Sutherland, K., Huynh, N., & Cistulli, P. A. (2019). Critical Issues in Dental and Medical Management of Obstructive Sleep Apnea. Journal of Dental Research. https://doi.org/10.1177/0022034519885644
276. Lavin, M. (2010). Voyeurism. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1030
277. Law, F., Praveen, K. T., O’Shea, J., & Melichar, J. (2011). Opioid dependence.. PubMed.
278. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
279. Ledezma, C., Soto, K., & Suárez, M. I. (2015). Depresión en el adulto mayor en Costa Rica: un problema social. Revista Hispanoamericana de Ciencias de la Salud.
280. Lee, M. S., & Ahn, W. (2011). Designation of a new drug as a controlled substance. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2011.54.2.189
281. LEHMAN, M., Foster, C., & Keul, J. (1993). Overtraining in endurance athletes: a brief review. Medicine & Science in Sports & Exercise. https://doi.org/10.1249/00005768-199307000-00015
282. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
283. Lempert, T. (2012). Recurrent Spontaneous Attacks of Dizziness. CONTINUUM Lifelong Learning in Neurology. https://doi.org/10.1212/01.con.0000421620.10783.ac
284. Lervik, A., Haga, H. A., & Becker, M. (2010). Abnormal motor activity during anaesthesia in a dog: a case report. Acta veterinaria Scandinavica. https://doi.org/10.1186/1751-0147-52-64
285. Lewis, D., & Woods, S. E. (1994). Fetal alcohol syndrome.. PubMed.
286. Liberalesso, P. B. N. (2018). Status epilepticus. Diagnosis and treatment. Residência Pediátrica. https://doi.org/10.25060/residpediatr-2018.v8s1-06
287. Lidija, G. G. S. (2011). Physiotherapeutic intervention with neurodevelopment risky infants in NICU.
288. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
289. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
290. Loconte, S. (2019). Primary fibromyalgia syndrome: A new holistic approach [abstract]. Journal of Ozone Therapy. https://doi.org/10.7203/jo3t.3.4.2019.15526
291. Lopes, R., Azevedo, J., Curral, R., Esteves, M., Coelho, R., & Roma‐Torres, A. (2013). OBSTRuCTive Sleep ApneA mAnifeSTed AS An ATypiCAl mAjOR depReSSive diSORdeR: A CASe RepORT And Review Of The liTeRATuRe. Arquivos de Medicina.
292. Lucassen, P., Ligthart, S. A., Kramers, C., & Speckens, A. (2021). [Why do patients find it difficult to discontinue their medication?]. PubMed.
293. Lukito, P. M., & Wreksoatmodjo, B. R. (2024). Gangguan Neurologis Pasca-COVID-19. Cermin Dunia Kedokteran. https://doi.org/10.55175/cdk.v51i8.1532
294. Lundh, H., & Tunving, K. (1981). An extrapyramidal choreiform syndrome caused by amphetamine addiction. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.44.8.728
295. López, C. A., Fernández, D. S., López, M. M., Gázquez, M. C. G., & Pérez, A. V. (2019). Cuidados de enfermería en recién nacidos con síndrome de abstinencia.
296. López, S. S. D. M., & Márquez, J. (2016). Evolución y situación actual del consumo deantidepresivos en España.
297. Maceira, E., Lesar, T. S., & Smith, H. S. (2012). Medication related nausea and vomiting in palliative medicine.. PubMed. https://doi.org/10.3978/j.issn.2224-5820.2012.07.11
298. Macho, L. P., & Andrés, S. B. (2010). Trastornos digestivos en la enfermedad de Parkinson: atonía gástrica, malabsorción y estreñimiento. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009740
299. Macias, C., Montaño, M. G., & Vega, D. (2015). Differential Diagnosis Between Neuroleptic Malignant Syndrome and Catatonia. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)30515-0
300. Madan, A., Frueh, B. C., Fowler, J. C., Stomberg, S., Bradshaw, M. R., Kelly, K. R., Weinstein, B., Luttrell, M., Danner, S. G., & Beidel, D. C. (2020). “Operator syndrome”: A unique constellation of medical and behavioral health-care needs of military special operation forces. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/0091217420906659
301. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
302. Mahon, S. M., & Carr, E. (2021). Fatigue/Lack of Endurance: Common Side Effect. Clinical journal of oncology nursing. https://doi.org/10.1188/21.cjon.s2.25
303. Majumdar, S., Chakrabartty, S., Chakravarti, S., & Roy, S. (2017). Excessive Cry in a 5-Month-Old Infant Possibly due to Abdominal Epilepsy. Journal of Pediatric Epilepsy. https://doi.org/10.1055/s-0037-1608868
304. Mandge, V., & Husain, A. M. (2020). Drug Trials in Status Epilepticus: Current Evidence and Future Concepts. Journal of Clinical Neurophysiology. https://doi.org/10.1097/wnp.0000000000000713
305. Marchand, D. K., & Argáez, C. (2021). Codeine for Acute Extremity Pain [Internet].
306. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
307. Markeljević, J., Šarac, H., & Radoš, M. (2011). Tremor, seizures and psychosis as presenting symptoms in a patient with chronic Lyme neuroborreliosis (Lnb) [Tremor, epileptički napadaji i psihoza kao prezentiraju i simptomi u bolesnika s kroničnom Lyme neuroboreliozom].
308. Martins, B. A., Madureira, R. S., Freitas, R. C., & Guidoreni, C. G. (2017). Enxaqueca. Congresso Médico Acadêmico UniFOA.. https://doi.org/10.47385/cmedunifoa.451.4.2017
309. Marttila, R., Atula, S., Heikkinen, E., Jaakkola, M.-R., Pekka, J., Keränen, T., Martikainen, K., Pekkonen, E., & Sotaniemi, K. A. (2010). [Update on current care guidelines. Parkinson's disease].. Duodecim.
310. Mattison, A., & Cherner, M. (2005). Club drugs and HIV transmission. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0067
311. Mauri, M., & Ramacciotti, D. (2006). Sintomi Psichici e Somatici dei Disturbi dell'Umore: razionali di terapia. Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology.
312. McGillion, M., O’Keefe-McCarthy, S., & Carroll, S. (2013). Self-Management Training for Chronic Stable Angina: Theory, Process, and Outcomes. InTech eBooks. https://doi.org/10.5772/54635
313. McInnis, M. G. (2014). Lithium for Bipolar Disorder: A Re Emerging Treatment for Mood Instability: Low Dosage, Slow Titration Might Mitigate Side Effects. Current psychiatry.
314. McIntyre, R. S., & Calabrese, J. R. (2019). Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2019.1636017
315. McQuillan, R. (2020). Symptoms other than pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0065
316. Meade, M. S. (1993). Beriberi. Cambridge University Press eBooks. https://doi.org/10.1017/chol9780521332866.077
317. Medina, S., & Fernando, D. (2019). Caso Christopher : El deseo, de deseo imposible en la neurosis obsesiva..
318. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
319. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
320. Mei, S., Li, J., Middlebrooks, E. H., Almeida, L., Hu, W., Zhang, Y., Ramírez-Zamora, A., & Chan, P. (2019). New Onset On-Medication Freezing of Gait After STN-DBS in Parkinson's Disease. Frontiers in Neurology. https://doi.org/10.3389/fneur.2019.00659
321. Melchior, C., Chassagne, P., Damon, H., Higuero, T., Siproudhis, L., & Vitton, V. (2020). Opioid-induced constipation. HAL (Le Centre pour la Communication Scientifique Directe). https://doi.org/10.1684/hpg.2019.1898
322. Mercadante, S. (2019). Opioid Analgesics Adverse Effects: The Other Side of the Coin. Current Pharmaceutical Design. https://doi.org/10.2174/1381612825666190717152226
323. Mercieri, M., Mercieri, A., & Pedrini, L. A. (2005). Baclofen neurotoxicity in chronic hemodialysis. Hemodialysis International. https://doi.org/10.1111/j.1492-7535.2005.1121bb.x
324. Mercês, T. M. D. (2019). Controle hidroeletrolítico e respostas cardiovasculares à injeção central de angII, carbacol e hiperosmolaridade plasmática em ratos com epilepsia induzida por pilocarpina.
325. Michael, A., & Andrews, S. C. (2002). Paroxetine-Induced Vaginal Anaesthesia. Pharmacopsychiatry. https://doi.org/10.1055/s-2002-33196
326. Michie, S. (2002). CAUSES AND MANAGEMENT OF STRESS AT WORK. Occupational and Environmental Medicine. https://doi.org/10.1136/oem.59.1.67
327. Michiels, J., Berneman, Z., Gadisseur, A., Lam, K. H., Raeve, H. D., & Schroyens, W. (2014). Aspirin-Responsive, Migraine-Like Transient Cerebral and Ocular Ischemic Attacks and Erythromelalgia in JAK2&lt;sup&gt;V617F&lt;/sup&gt;-Positive Essential Thrombocythemia and Polycythemia Vera. Acta Haematologica. https://doi.org/10.1159/000360388
328. Mihanović, M., Bodor, D., Kezić, S., Restek-Petrović, B., & Silić, A. (2009). Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders.. PubMed.
329. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395
330. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395_update_001
331. Miller, M. W., Marx, B. P., & Keane, T. M. (2010). Posttraumatic Stress Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0699
332. MINEI, S., Kainuma, M., Sakamoto, H., Tamaki, N., TOMORI, H., CHOLSONG, Y., Nakahara, Y., & FURUSSYO, N. (2019). Consideration of a New Category of Patients for Whom Ryokeijutsukanto is Effective at a Different Stage Then was Previously Reported. Kampo Medicine. https://doi.org/10.3937/kampomed.70.141
333. Mitchell, P. B., Goodwin, G. M., Johnson, G. F., & Hirschfeld, R. M. A. (2008). Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2007.00559.x
334. Miwa, Y., Yanai, R., Fuyuya, H., Ohtsuka, K., & Kasama, T. (2012). [How to use of the psychotropic drug in rheumatic disease].. PubMed.
335. Miyasato, K. (2013). [Psychiatric and psychological features of nicotine dependence].. PubMed.
336. Modebelu, U., Nargarathan, P. K. M., Marleime, K., & Ramesh, K. (2019). Pharmacologic Therapy for Neonatal Abstinence Syndrome. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v9i3.2900
337. Molla, L., Preza, K., & Simaku, A. (2021). Low Back Pain Diagnostic Approach. Medicus. https://doi.org/10.58944/bcsf1353
338. Molleman, P. W., Kesteren, J. V., Ubink-Bontekoe, C., Zoomer-Hendriks, M. P. D., & Wetzels, R. B. (2015). [Canopy-enclosed bed for dementia patients with behavioural problems].. PubMed.
339. Monotti, R. (1993). [Drug emergencies].. PubMed.
340. Montes, A. B., & Rey, J. A. (2009). Iloperidone (Fanapt): An FDA-Approved Treatment Option for Schizophrenia. P & T.
341. Montgomery, S., Bebbington, P., Cowen, P. J., Deakin, J., Freeling, P., Hallström, C., Katona, C., King, D. S., Leonard, B., Levine, S., Phanjoo, A. L., Peet, M., Thompson, C. M., & Thompson, C. M. (1993). Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. Journal of Psychopharmacology. https://doi.org/10.1177/0269881193007001041
342. Moonen, J., Poelaert, J., & Matic, M. (2021). Het posterieur reversibel encefalopathiesyndroom. Tijdschrift voor Geneeskunde. https://doi.org/10.47671/tvg.77.21.191
343. Morell, I. B. (2011). Caracterització farmacològica de moduladors gabaèrgics per al tractament de l’insomni primari. TDX (Tesis Doctorals en Xarxa).
344. Mospan, C. M. (2021). Chapter 14: Headache. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123592.ch14
345. Motta, M. P., Quadros, A. A. J., Ferreira, L. S., & Oliveira, A. S. B. (2019). Fatigue in Post-Polio Syndrome. Brazilian Journal of Biological Sciences. https://doi.org/10.21472/bjbs.061203
346. Moumeni, I. N., Mapoure, Y. N., Moyse, E., Temgoua, M., Moulangou, J., & Abdel-Nasser, N. M. (2021). Stroke; early physiotherapy? what content? proposal of physiotherapy content in the acute phase (D1 at D14), part II: specific to the patient massively injured by the stroke.. HAL (Le Centre pour la Communication Scientifique Directe).
347. Mude, G., Pise, S., Makade, K., Fating, R., & Wakodkar, S. (2021). Termiticidal Activity of Ethanolic and n- Hexane Leaf Extraction of Calotropis procera, Cannabis indica and Mentha longifolia Against a Higher Termite Microtomes obesi. Journal of Developing Drugs. https://doi.org/10.35248/2329-6631.21.10.206
348. Mukim, M., Devi, S. L., Sharma, P., Joshef, M. R., Nagar, J. C., & Ahmad, N. (2019). ANESTHESIA AND ITS APPPLICATION. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2019.6.4.5
349. Munir, S., & Takov, V. (2021). Generalized Anxiety Disorder. StatPearls.
350. Munir, S., Takov, V., & Coletti, V. A. (2021). Generalized Anxiety Disorder (Nursing).
351. Murawiec, S. (2014). Leczenie ostrego lęku — opis trzech przypadków zastosowania tabletek podjęzykowych alprazolamu do opanowania nasilonych dolegliwości lękowych. Psychiatria.
352. Mut, E. A., Pălădoiu, C., & Stănescu, M. (2021). Somatoform and conversion disorders as psychological defences. Journal of Educational Sciences & Psychology. https://doi.org/10.51865/jesp.2021.1.19
353. Muttalib, M. A. (2019). Neuropathic pain treatment between drug therapy and supplement effects. International Journal of Basic & Clinical Pharmacology. https://doi.org/10.18203/2319-2003.ijbcp20194806
354. Nagireddy, R. B. R., & Joshi, D. (2020). Phenytoin induced chorea: an uncommon manifestation. Authorea (Authorea). https://doi.org/10.22541/au.159109589.94248103
355. Nakata, C., Nara, K., Kinoshita, F., Kikuchi, K., & Asai, M. (2015). [Alcohol withdrawal syndrome showing various progress: A case report].. PubMed.
356. Nakayama, H., Mihara, S., Sakuma, H., Kitamura, D., & Higuchi, S. (2014). SY08-3 * CO-MORBIDITY OF INTERNET ADDICTION. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu052.39
357. Nater, U. M., Miller, A. H., Reeves, W. C., & Raison, C. L. (2010). Chronic Fatigue Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0176
358. Neela, B., Vaddi, M., Kagitapu, S., & Bandaru, S. S. (2020). DRESS syndrome: a pediatric case report.. European Journal of Pediatric Dermatology/PD. European journal of pediatric dermatology. https://doi.org/10.26326/2281-9649.30.4.2164
359. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
360. Ng, M. H. S., Ming, J., & Beng, N. (2021). Insomnia in the Elderly: Evaluation and Management. The Singapore Family Physician. https://doi.org/10.33591/sfp.47.2.u3
361. Nguyen, D. C., Timmer, T. K., Davison, B. C., & McGrane, I. R. (2017). Possible <i>Garcinia cambogia</i>-Induced Mania With Psychosis: A Case Report. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190017734728
362. Nielsen, J. F., Klemar, B., Hansen, H., & Sinkjær, T. (1995). A new treatment of spasticity with repetitive magnetic stimulation in multiple sclerosis.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.58.2.254-a
363. Ninaprilia, Z., & Rohmani, C. F. (2015). Gangguan Mood Episode Depresi Sedang. Jurnal Medula.
364. Noble, F., & Roques, B. P. (2003). Inhibitors of Enkephalin Catabolism. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_5
365. Obering, C., Chen, J. J., & Swope, D. (2006). Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.26.6.840
366. Ogbonna, C. I., & Lembke, A. (2017). Tapering Patients Off of Benzodiazepines.. PubMed.
367. Oh, S.-H. (2019). 12 - CAN RORSCHACH DIFFERENTIATE BIPOLAR DISORDER FROM DEPRESSIVE DISORDER? : COMPARISON OF RORSCHACH SCORES BETWEEN BIPOAR DEPRESSION AND UNIPOLAR DEPRESSION. https://doi.org/10.26226/morressier.5d1a038757558b317a13f97e
368. Ojimba, C., Isidahome, E. E., Odenigbo, N., Umudi, O. D., & Olayinka, O. (2019). Catatonia in major depressive disorder: diagnostic dilemma. A case report. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2019.10.00651
369. Olesen, A. S., & Jensen, O. H. (2006). [Pain centers--why and when?].. Ugeskrift for Læger.
370. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
371. Olowoyo, P., Oguntoye, O., Akinbote, J. A., & Akinyemi, M. O. R. (2018). Recurrent Prolonged Epileptic Fugue State Misdiagnosed as Psychosis? Tale of a Middle-Aged Female Nigerian African. International Journal of Innovative Research in Medical Science. https://doi.org/10.23958/ijirms/vol02-i09/04
372. Onishi, H., Wada, M., Wada, T., Wada, M., Ishida, M., Kawanishi, C., Mizuno, K., Ito, H., Narabayashi, M., & Sasaki, Y. (2010). Diagnosis and treatment of akathisia in a cancer patient who cannot stand up or sit down, because of poor performance status: Factors that make the diagnosis of akathisia difficult, and diagnosis clues. Palliative & Supportive Care. https://doi.org/10.1017/s1478951510000350
373. Ori, Y., & Solun, B. (2011). Severe hiccups associated with intra-articular corticosteroid injection — A case report. Open Medicine. https://doi.org/10.2478/s11536-011-0105-2
374. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
375. Otsuka, K., Kato, S., Abe, T., SUGIYAMA, H., Watanabe, Y., Kobayashi, T., & Okajima, Y. (2002). [Classification of long-term clinical course of 'atypical psychosis': a 20-year follow-up study at a medical school hospital].. PubMed.
376. Otten, R. I., Jansen, I., & Zeeman, M. (2019). [A vulnerable elderly man with prednisone-induced delirium].. PubMed.
377. Ozdemir, D., Allain, F., Kieffer, B. L., & Darcq, E. (2023). Advances in the characterization of negative affect caused by acute and protracted opioid withdrawal using animal models. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2023.109524
378. O’Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence.. PubMed.
379. O’Shea, J., Law, F., & Melichar, J. (2009). Opioid dependence.. PubMed.
380. PADMAWATI, N. N., Ardani, I. G. A. I., Ariyani, A., Ariani, P., & Purnamasidhi, ‪. A. W. (2021). Psychopharmaceutical Therapy and Supportive Psychotherapy for COVID-19 Patients with Depression. International Journal of Medical Reviews and Case Reports. https://doi.org/10.5455/ijmrcr.covid-19-psychopharmaceutical-therapy-172-1608192666
381. Pagel, J., Pandi‐Perumal, S. R., & Monti, J. M. (2018). Treating insomnia with medications. Sleep Science and Practice. https://doi.org/10.1186/s41606-018-0025-z
382. Pan, E., Algül, A., Başoğlu, C., Ebrinç, S., Ateş, M. A., Semiz, Ü., Şenol, M. G., & Çetin, M. (2010). P01-294 - Depression and Agoraphobia in a Patient with Myasthenia Gravis. European Psychiatry. https://doi.org/10.1016/s0924-9338(10)70502-2
383. Pan, E., Algül, A., Ebrinç, S., Başoğlu, C., Semiz, Ü., Ateş, M. A., Şenol, M. G., & Çetin, M. (2010). P01-293 - Psychiatric mis-diagnoses and escitolopram treatment of mood and anxiety disorders in myasthenia gravis: a case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(10)70501-0
384. Pang, N. T. P., & Masiran, R. (2020). Mood disorder induced by prednisolone – an easily overlooked complication. Current Problems of Psychiatry. https://doi.org/10.2478/cpp-2020-0012
385. Paradela, E. M. P. (2011). Depressão em idosos. Revista Hospital Universitário Pedro Ernesto (TÍTULO NÃO-CORRENTE). https://doi.org/10.12957/rhupe.2011.8850
386. Paredes, D. F. D., Farfán, J. C. P., Orellana, J. M. F., & Legarda, A. A. B. (2019). Trastorno disfórico premenstrual. RECIAMUC. https://doi.org/10.26820/reciamuc/3.(1).enero.2019.199-217
387. Park, J. C., Choi, Y. S., & Kim, J. H. (2010). Current pharmacological management of chronic pain. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2010.53.9.815
388. Park, J. H., Kim, H.-C., Lee, J. H., Kim, J. S., Roh, S. Y., Yi, C. H., Kang, Y. K., & Kwon, B. S. (2009). Development of Korean Academy of Medical Sciences Guideline for Rating Physical Disability of Upper Extremity. Journal of Korean Medical Science. https://doi.org/10.3346/jkms.2009.24.s2.s288
389. Park, Y. S., Kim, Y.-B., & Kim, J. (2014). Status Epilepticus Caused by Nefopam. Journal of Korean Neurosurgical Society. https://doi.org/10.3340/jkns.2014.56.5.448
390. Partinen, M., Huutoniemi, A., Kajaste, S., Lagerstedt, R., Markkula, J., Mäkinen, E., Paakkari, I., Partonen, T., Polo, P., Saarenpää‐Heikkilä, O., Seppälä, M., Kukkonen-Harjula, K., & Tuunainen, A. (2016). [Update on Current Care Guideline: Insomnia].. PubMed.
391. Parvataneni, S., & Duncan, M. (2020). S2043 Anxiolytic - A Gastric Fundus Relaxing Agent for Epigastric Pain Syndrome. The American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000868
392. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
393. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
394. Paw, H., & Shulman, R. (2014). Management of status epilepticus. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781316182673.042
395. Peitl, M. V., Prološčić, J., Zelić, S. B., Skarpa-Usmiani, I., & Peitl, V. (2011). Symptoms of agitated depression and/or akathisia.. PubMed.
396. Penders, T. M., Rohaidy, R., & Agarwal (2013). Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depression. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s43113
397. Perananthan, V., & Buckley, N. A. (2021). Opioids and antidepressants: which combinations to avoid. Australian Prescriber. https://doi.org/10.18773/austprescr.2021.004
398. Pergolizzi, J. V., Annabi, H., Gharibo, C., & LeQuang, J. A. (2018). The Role of Lofexidine in Management of Opioid Withdrawal. Pain and Therapy. https://doi.org/10.1007/s40122-018-0108-7
399. Pergolizzi, J. V., Taylor, R. J., LeQuang, J. A., Gould, E. M., & Raffa, R. B. (2019). Treating Insomnia in Older Adult Patients: Limiting Benzodiazepine Use. Pharmacology &amp Pharmacy. https://doi.org/10.4236/pp.2019.103010
400. Pergolizzi, J. V., Taylor, R., LeQuang, J. A., Bisney, J., Raffa, R. B., Pergolizzi, F., Colucci, D., & Batastini, L. (2018). Driving under the influence of opioids: What prescribers should know. Journal of Opioid Management. https://doi.org/10.5055/jom.2018.0474
401. Petruševičienė, D., & Kriščiūnas, A. (2003). [Occupational therapy for patients after stroke].. PubMed.
402. Peveler, R. (2002). ABC of psychological medicine: Depression in medical patients. BMJ. https://doi.org/10.1136/bmj.325.7356.149
403. Peña, D. A., Pérez, M. L., & Pinzón, L. F. C. (2014). Línea de investigación psicología clínica y de la salud..
404. Peña, M. A. M. (2013). Síndrome de sobreentrenamiento. IATREIA.
405. Pich, E. M., Heidbreder, C., Mugnaini, M., & Teneggi, V. (2003). Molecular and Behavioral Aspects of Nicotine Dependence and Reward. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_16
406. Pickard, H. (2011). What Is Personality Disorder?. Philosophy, psychiatry & psychology. https://doi.org/10.1353/ppp.2011.0040
407. Plaut, T., & Weiss, J. M. (2021). Electrodiagnostic Evaluation Of Critical Illness Neuropathy. StatPearls.
408. Plavec, D., & Vuljanko, I. M. (2010). ANAFILAKSIJA POTAKNUTA NAPOROM.
409. Poewe, W., Olanow, C. W., Rascol, O., & Stocchi, F. (2020). From OFF to ON—Treating OFF Episodes in Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2020.16.suppl.1.2
410. Poirier, M. F., & Ginestet, D. (1995). [Drugs diverted from reaching drug addicts].. PubMed.
411. Politis, M., Wu, K., Molloy, S., Bain, P. G., Chaudhuri, К. R., & Piccini, P. (2010). Parkinson's disease symptoms: The patient's perspective. Movement Disorders. https://doi.org/10.1002/mds.23135
412. Post, R. M. (2002). Introduction: Emotion and Psychopathology. https://doi.org/10.1093/oso/9780195126013.003.0048
413. Prajapati, B., Agarwal, A., Garg, D., Garg, A., Pandit, A., Radhakrishnan, D. M., & Srivastava, A. (2024). Delayed post-hypoxic parkinsonism with leukoencephalopathy associated with carbon monoxide poisoning. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_37_24
414. Prasad, K., Prasad, M., Ramaratnam, S., & Marson, A. G. (2015). Status epilepticus. https://doi.org/10.1002/9781119067344.ch9
415. Prathima, P. R., Johnson, D. B., Suresh, R., Venkatnarayanan, R., & Ahammad, P. M. A. (2013). Acute and Subacute Toxicity study of Milnacipran Hydrochloride in Wistar rats by Oral Route. Research Journal of Pharmacology and Pharmacodynamics.
416. Pujol, R., & Puel, J. (1999). Excitotoxicity, Synaptic Repair, and Functional Recovery in the Mammalian Cochlea: A Review of Recent Findings. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1999.tb08646.x
417. Pysden, K. (2015). Alternating hemiplegia of childhood. Journal of Pediatric Neurology. https://doi.org/10.3233/jpn-2010-0337
418. Pérez, J. M. C. (2003). Clínica de la adicción a pasta base de cocaína. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272003000100007
419. Păunica, S., Giurgiu, M., Vasilache, A., Păunică, I., Motofei, I. G., Vasilache, A., Dumitriu, H., & Dumitriu, A. S. (2016). Finasteride adverse effects and post-finasteride syndrome; implications for dentists. Journal of Mind and Medical Sciences. https://doi.org/10.22543/2392-7674.1039
420. Qamar, A., Kotha, K., & Ioachimescu, O. C. (2011). Obstructive Sleep Apnea. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805267711101010021
421. Rachmani, S., & Mayasari, D. (2017). Kombinasi Farmakoterapi dan Psikoterapi Pada Pengobatan Episode Depresif Sedang Dengan Gejala Somatis. Jurnal Medula.
422. Rahmani, M., Ahmadi, S., & Moghaddam, H. H. (2011). Serotonin Syndrome Following Single Ingestion of High Dose.
423. Raininko, R., Gosky, M., & Padiath, Q. S. (1993). LMNB1-Related Autosomal Dominant Leukodystrophy.
424. Rajamäki, T., Moilanen, T., Puolakka, P. A., Hietaharju, A., & Jämsen, E. (2021). Is the Preoperative Use of Antidepressants and Benzodiazepines Associated with Opioid and Other Analgesic Use After Hip and Knee Arthroplasty?. Clinical Orthopaedics and Related Research. https://doi.org/10.1097/corr.0000000000001793
425. Ranganathan, A., & Beitman, B. D. (1998). Panic disorder: a different perspective.. PubMed.
426. Ransom, S. B., & Moldenhauer, J. S. (1998). Premenstrual Syndrome. The Physician and Sportsmedicine. https://doi.org/10.3810/psm.1998.04.872
427. Rao, S. (2016). Prolonged coma after anesthesia. Journal of Anaesthesiology Clinical Pharmacology. https://doi.org/10.4103/0970-9185.173339
428. Rascol, O., Payoux, P., Ory, F., Ferreira, J. J., Brefel‐Courbon, C., & Montastruc, J. (2003). Limitations of current Parkinson's disease therapy. Annals of Neurology. https://doi.org/10.1002/ana.10513
429. Rashidpour, P., Poursharif, Z., Ayatollahi, M., & Farzannejad, E. (2021). Bupropion-induced acute dystonia in a patient with bulimia nervosa. Journal of Family Medicine and Primary Care. https://doi.org/10.4103/jfmpc.jfmpc_1173_20
430. Rasmussen, K. (2002). Morphine Withdrawal as a State of Glutamate Hyperactivity. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_22
431. Rastegar, D. A. (2020). Opioids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0006
432. Ravishankar, K., & Bhatnagar, M. (2013). Faculty Opinions recommendation of Advanced interventions for headache.. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. https://doi.org/10.3410/f.717992832.793473687
433. Reddy, M. S. (2014). Irritability as a Criterion in Diagnosis of Child and Adolescent Bipolar Disorder: Thorny Road Ahead. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.130954
434. Reddy, S., Elsayem, A., & Talukdar, R. (2005). Palliative Care. CRC Press eBooks. https://doi.org/10.1201/b14119-59
435. Reinares, M., Martínez‐Arán, A., & Vieta, E. (2019). Psychoeducation for Patients and Family Members. Cambridge University Press eBooks. https://doi.org/10.1017/9781108589802.004
436. Reula, L. M., García, H. S., & Fernández, A. P. (2017). Stressors in patients with schizoaffective disorder. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1610
437. Riddle, E., Bush, J., Tittle, M., & Dilkhush, D. (2010). Alcohol Withdrawal: Development of a Standing Order Set. Critical Care Nurse. https://doi.org/10.4037/ccn2010862
438. Rizvi, S., Farooq, F., Shagufta, S., Khan, A., Masood, Y., & Saeed, H. (2018). Postictal Mania Versus Postictal Psychosis. Cureus. https://doi.org/10.7759/cureus.3338
439. Robinson, C. P., & Hocker, S. E. (2019). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0098
440. Rodríguez, E. O., Esquivel, P. S., & Triana, I. M. (2024). Un panorama actualizado de la dispepsia. Revista médica de Panamá. https://doi.org/10.37980/im.journal.rmdp.20242296
441. Rodríguez‐Leyva, I., Sánchez-Aguilar, M., Hernández-Sierra, J. F., Mandeville, P. B., Leyva, M. D. R. R., Shiguetomi-Medina, J. M., & Tapia-Pérez, J. H. (2010). Topiramate vs. Amitriptyline in prophylactic treatment of migraine: A controlled clinical trial. DELETED.
442. Rohmayanti, I. D., & Kurniawan, S. N. (2023). POST HERPETIC NEURALGIA. JPHV (Journal of Pain Vertigo and Headache). https://doi.org/10.21776/ub.jphv.2023.004.01.1
443. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
444. Rosmina, P., & Timothy, S. (2024). Panic Disorder Versus Thyroid Medication Overuse: A Case Report. Scientia Psychiatrica. https://doi.org/10.37275/scipsy.v5i2.170
445. Rowe, P. C., Underhill, R., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2017.00121
446. Ruiz, C. B., Torralbo, M. B., Garcia, R. R., Llobet, A. H., Fernández, I. A., Nielsen, N. P., Landeo, A. R., Ramírez, M. M., Fuentes, D. G., Soler, M. A., & Cañete, J. (2020). Psicosis dual y cariprazina. Caso clínico. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p141
447. Ruiz‐Rizzo, A. L., & Restrepo, F. L. (2008). Memoria explícita en el trastorno depresivo mayor. IATREIA. https://doi.org/10.17533/udea.iatreia.4479
448. Sabo-Graham, T., & Seay, A. R. (1998). Consultation with the Specialist: Management of Status Epilepticus in Children. Pediatrics in Review. https://doi.org/10.1542/pir.19.9.306
449. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
450. Sahu, D., Garg, J., & Anand, K. S. (2023). An Interesting Case of Eating Epilepsy. Indian Journal of Medical Specialities. https://doi.org/10.4103/injms.injms_49_23
451. Saitz, R. (1998). Introduction to alcohol withdrawal.. PubMed.
452. Sanchis‐Segura, C., & Spanagel, R. (2006). REVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2006.00012.x
453. Santambrogio, A. (2016). Psicofarmaci e vita quotidiana. SALUTE E SOCIETÀ. https://doi.org/10.3280/ses2016-003012
454. Saper, J. R., & Lake, A. E. (2008). Continuous Opioid Therapy (COT) is Rarely Advisable for Refractory Chronic Daily Headache: Limited Efficacy, Risks, and Proposed Guidelines. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2008.01153.x
455. Sapkota, N. K. (2017). Depression led pitting edema: A rarest case presentation.. PubMed.
456. Sarris, J., O’Neil, A., Coulson, C., Schweitzer, I., & Berk, M. (2014). Lifestyle medicine for depression. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-107
457. Schenck, C. H. (2003). Assessment and Management of Insomnia. JAMA. https://doi.org/10.1001/jama.289.19.2475
458. Schuckit, M. A. (2016). Treatment of Opioid-Use Disorders. New England Journal of Medicine. https://doi.org/10.1056/nejmra1604339
459. Schwager, H., & BSN, L. T. S. (2019). 09 - TREATMENT OF IATROGENIC OPIOID DEPENDANCE USING BUPERNORPHINE IN PATIENTS WITH CHRONIC PAIN A TELE-BEHAVIORAL MEDICINE PROTOCOL. https://doi.org/10.26226/morressier.5d1a038357558b317a140c62
460. Schwartz, R. H. (1984). Psychoactive Drug Use During Adolescence: The Pediatrician's Role. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1984.02140400083021
461. Schweitzer, J. B. (2010). Attention‐Deficit/Hyperactivity Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0096
462. Schönknecht, P., Allgaier, A., Henkel, V., Hegerl, U., & Mergl, R. (2011). Psychopharmako- und Psychotherapie bei Patienten mit minorer Depression. Nervenheilkunde. https://doi.org/10.1055/s-0038-1628444
463. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
464. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
465. Serageldin, M., Hikmet, W., & Alani, S. (2019). Insomnia is a Prodromal Symptom for Psychosis. Journal of the Bahrain Medical Society. https://doi.org/10.26715/jbms.31_31012019
466. Serrano, L., & Néstor, A. (2019). Proceso de Atención de Enfermería en neonato con diagnóstico de Síndrome de Abstinencia Neonatal, perteneciente al área CIN en el Hospital General Guasmo Sur..
467. Sh.H., S., L.A., T., N.I., K., V.K., A., & Nurkhodjaev, S. (2020). Diagnostics of Dysthymic Disorders and Therapy of Patients with Opium Addiction with AnxietyDepressive Variant of Post-Withdrawal Syndrome. International Journal of Current Research and Review. https://doi.org/10.31782/ijcrr.2020.122320
468. Shalamberidze, D., Awad, Y. A., Höpfner, J., Kluge, G., & Benes, L. (2021). Suggestion For a New Classification of Postoperative Neurological Complications (CPNC) in Neurosurgery. Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-353350/v1
469. Shams, J., Rahmani, B., Asefi, F., & Daneshfar, S. (2010). CATATONIA DEVELOPMENT IN A SCHIZOAFFECTIVE PATIENT FOLLOWING ELECTROCONVULSIVE THERAPY: CASE REPORT.
470. Shamsi, S., & Khan, S. (2019). Use of Pain Assessment Tools in Physiotherapy.
471. Sharma, S., Kumar, P., Raut, N., & Prasad, S. (2021). Psychotic symptoms in heroin withdrawal: A case report. Indian Journal of Case Reports. https://doi.org/10.32677/ijcr.2021.v07.i02.010
472. Sharp, C. W., Rosenberg, N. L., & Beauvais, F. (2008). Substance Abuse: Inhalant‐Related Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch61
473. Sharp, L. K., & Lipsky, M. S. (2002). Screening for depression across the lifespan: a review of measures for use in primary care settings.. PubMed.
474. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
475. Shorvon, S. (2011). Super‐refractory status epilepticus: An approach to therapy in this difficult clinical situation. Epilepsia. https://doi.org/10.1111/j.1528-1167.2011.03238.x
476. Shou-zh, W. (2008). Drug Psychosis by Antipsychotic Drugs:Report of 40 Cases. Zhongguo quanke yixue.
477. Silva, H. M. D., & Cardoso, L. V. (2021). RISADA PEGA: A Mnemonic Method in Portuguese for Alarm Criteria in Emergency Headaches. Deleted Journal. https://doi.org/10.48208/headachemed.2021.supplement.29
478. Sivolap, Y. P. (2010). P03-259 - Psychopathological Aspects Of Opioid Addiction. European Psychiatry. https://doi.org/10.1016/s0924-9338(10)71313-4
479. Snidvongs, S., & Mehta, V. (2011). Recent advances in opioid prescription for chronic non-cancer pain. Postgraduate Medical Journal. https://doi.org/10.1136/pgmj.2010.112045
480. Soares, E. B., Pires, J. B., Menezes, M. D. A., Santana, S. K. S. D., & Fraga, J. (2010). Fonoaudiologia X ronco/apneia do sono. Revista CEFAC. https://doi.org/10.1590/s1516-18462010000200019
481. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
482. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
483. Staab, J. P., Eckhardt‐Henn, A., Horii, A., Jacob, R. G., Strupp, M., Brandt, T., & Bronstein, A. M. (2017). Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Bárány Society. Journal of Vestibular Research. https://doi.org/10.3233/ves-170622
484. Stafie, C. S., & Stafie, I. I. (2019). POST COITAL ALLERGY – A CASE REPORT OF POST ORGASMIC ILLNESS SYNDROME. The Medical-Surgical Journal.
485. Stannard, C., Coupé, M., & Pickering, T. (2013). Benefits and adverse effects of opioids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199678075.003.0007
486. Steenkamp, M. M., & Litz, B. T. (2013). Early Interventions with Military Personnel. Oxford University Press eBooks. https://doi.org/10.1093/med:psych/9780199928262.003.0052
487. Stevens, M. (1993). Tension-type headaches.. PubMed.
488. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
489. Stone, J., Carson, A., & Sharpe, M. (2005). Functional symptoms in neurology: management. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.061663
490. Straszek, S. P., Licht, R. W., Nielsen, R. E., & Vinberg, M. (2022). [Bipolar depression, a challenge diagnostic and treatmentwise].. Research Portal Denmark.
491. Strupp, M., López‐Escámez, J. A., Kim, J., Straumann, D., Jen, J. C., Carey, J. P., Bisdorff, A., & Brandt, T. (2017). Vestibular paroxysmia: Diagnostic criteria. Journal of Vestibular Research. https://doi.org/10.3233/ves-160589
492. Stäubli, M. (1993). [Panic attacks].. PubMed.
493. Suchowersky, O., Reich, S. G., Perlmutter, J. S., Zesiewicz, T., Gronseth, G., & Weiner, W. J. (2006). Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]. Neurology. https://doi.org/10.1212/01.wnl.0000215437.80053.d0
494. Swegle, J., & Logemann, C. D. (2006). Management of common opioid-induced adverse effects.. PubMed.
495. Sánchez-Narváez, F. (2018). Síndrome de burnout. Editorial Académica Española eBooks.
496. Sánchez-Pérez, M., Roncero, C., Gálvez-Ortiz, V., Cardoner, N., Crespo-Blanco, J. M., Navarro-Odriozola, V., García–Parés, G., Eucb, G., & Psiquiatría, S. D. (2011). Use of bubropion in elderly patients.
497. Söderpalm, B. (2002). Anticonvulsants: aspects of their mechanisms of action. European Journal of Pain. https://doi.org/10.1053/eujp.2001.0315
498. Tan, B. L. W., & Gudi, A. (2021). A rare case: Mania associated with pazopanib. Proceedings of Singapore Healthcare. https://doi.org/10.1177/20101058211023778
499. Tassorelli, C., Sances, G., Sandrini, G., & Nappi, G. (2015). Rehabilitation from symptomatic drugs overuse: yes, no, may be. The Journal of Headache and Pain. https://doi.org/10.1186/1129-2377-16-s1-a34
500. Tatsuzawa, Y., Ono, Y., Takahashi, T., Yoshino, A., & Nomura, S. (2011). Case of isolated adrenocorticotropic hormone deficiency mimicking major depressive disorder. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2011.02207.x
501. Taylor, M. E., & Whitney, J. (2021). Impaired Cognition and Falls. Cambridge University Press eBooks. https://doi.org/10.1017/9781108594455.009
502. Tedyanto, E. H., Adnyana, I. M. O., & Widyadharma, I. P. E. (2023). Tension-type Headache and Migraine as Manifestations of Chronic Post-Traumatic Headache. Cermin Dunia Kedokteran. https://doi.org/10.55175/cdk.v50i2.528
503. Teixeira, M. Z. (2013). Rebound effects of modern drugs: serious adverse events unknown by health professionals. Revista da Associação Médica Brasileira (English Edition). https://doi.org/10.1016/s2255-4823(13)70530-7
504. Terman, M., & Terman, J. S. (2013). Chronotherapeutics. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175869.026
505. Thakkar, K., Shah, K., Rana, D., Malhotra, S., & Patel, P. (2017). Amlodipine drug therapeutic failure: a rare case report. International Journal of Basic & Clinical Pharmacology. https://doi.org/10.18203/2319-2003.ijbcp20175700
506. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. DeckerMed Family Medicine. https://doi.org/10.2310/fm.13043
507. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/cannabis.13043
508. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/psych.13043
509. Thomson, S. R. (2017). Sodium Valproate Induced Alopecia: A Case Series. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. https://doi.org/10.7860/jcdr/2017/28564.10658
510. Tiglao, S. M., Meisenheimer, E. S., & Oh, R. (2021). Alcohol Withdrawal Syndrome: Outpatient Management.. American family physician.
511. Timo, P. (2021). Hallucination: A Mental Illness. Clinical Psychiatry. https://doi.org/10.36648/2471-9854.21.7.81
512. Todorović, S. (2016). Socijalno medicinske karakteristike i razlike između alkoholičara sa periodičnim i kontinuiranim pijenjem / Social and Medical Characteristics and Differences Between Alcoholics With Periodic and Continuous Drinking. SESTRINSKI ŽURNAL. https://doi.org/10.7251/sez0116005t
513. Tondo, L., & Baldessarini, R. J. (2020). Discontinuing psychotropic drug treatment. BJPsych Open. https://doi.org/10.1192/bjo.2020.6
514. Tong, G., Groom, K. N., Ward, L., & Naeem, M. Y. (2021). “This Is Not the Original Timeline”: A Case Report of an Extended Dissociative Episode in a Healthy Young Male Accompanied with Severe Decline in Mental State. Case Reports in Psychiatry. https://doi.org/10.1155/2021/6619579
515. Toom, K., Braschinsky, M., Obermann, M., & Katsarava, Z. (2020). Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. https://doi.org/10.1177/0333102420942238
516. Toro, V. D., Aedo, K., & Urrejola, P. (2021). Trastorno de Evitación y Restricción de la Ingesta de Alimentos (ARFID): Lo que el pediatra debe saber. Andes pediatrica. https://doi.org/10.32641/andespediatr.v92i2.2794
517. Touloumis, C. (2021). Treatment resistant depression: Challenges and therapeutic choices. Psychiatriki. https://doi.org/10.22365/jpsych.2021.047
518. Treiman, D. M. (1993). Generalized Convulsive Status Epilepticus in the Adult. Epilepsia. https://doi.org/10.1111/j.1528-1157.1993.tb05902.x
519. Trinka, E., Cock, H. R., Hesdorffer, D. C., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015). A definition and classification of status epilepticus – Report of the<scp>ILAE</scp>Task Force on Classification of Status Epilepticus. Epilepsia. https://doi.org/10.1111/epi.13121
520. Trivedi, K., Kataria, L., & Patel, D. (2020). A COMPARATIVE STUDY EVALUATING THE DEPRESSIVE SYMPTOMS AND FUNCTIONAL OUTCOME IN PATIENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS V/S SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS AS ANTIDEPRESSANT AGENTS IN MAJOR DEPRESSIVE DISORDER.
521. Trujillo, K. A. (2012). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence A Review of the Research, A Cellular Model, and Implications for the Treatment of Pain and Addiction.
522. Turner, R. M., & Elson, E. (1993). Sleep disorders. Steroids cause sleep disturbance.. BMJ. https://doi.org/10.1136/bmj.306.6890.1477-d
523. Tyler, G. S. (1990). Return to Low-Altitude Sickness: An Entity That Doesn't Exist. JAMA. https://doi.org/10.1001/jama.1990.03440170023025
524. Uddin, M., Zaman, F., Jahan, K., Tarafder, M., Hossain, A., & Rahman, F. (2018). Reccurent episodes of vomiting and hyperpigmentation---Addison,s disease, a case report. TAJ Journal of Teachers Association. https://doi.org/10.3329/taj.v29i2.39111
525. Unknown (1983). Management of agoraphobia. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.21.16.61
526. Unknown (1983). Neonatal Drug Withdrawal. PEDIATRICS. https://doi.org/10.1542/peds.72.6.895
527. Upadhyay, S., Elmatite, W., Taqi, S., Jagia, M., & Mallick, P. (2011). Dexmedetomidine infusion to facilitate opioid detoxification and withdrawal in a patient with chronic opioid abuse. Indian Journal of Palliative Care. https://doi.org/10.4103/0973-1075.92353
528. Valdez, J. M. (2013). [Status epilepticus in childhood].. PubMed.
529. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
530. Vendruscolo, L. F., & Koob, G. F. (2019). Alcohol Dependence Conceptualized as a Stress Disorder. https://doi.org/10.1093/oxfordhb/9780190681777.013.9
531. Vergano, S. A. S., Sluijs, P. J. V. D., & Santen, G. W. (2019). ARID1B-Related Disorder.
532. Verhagen, E. H., Hesselmann, G. M., Besse, T. C., & Graeff, A. D. (2005). [Palliative sedation].. PubMed.
533. Vicente, J. F. M. (2014). Estado epiléptico refractario en el entorno de la terapia intensiva. Medicina Crítica.
534. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
535. Vázquez, G., Forte, A., Camino, S., Tondo, L., & Baldessarini, R. J. (2017). Treatment implications for bipolar disorder co-occurring with anxiety syndromes and substance abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198748625.003.0017
536. Wadhwa, R., & Khandare, M. (2014). Stress Management through Yoga. Global Journal of Human-Social Science.
537. Wahyuningsih, S., Nurun, N., Ainul, A., Rendra, R., & Dwiki, D. (2020). Relaksasi Nafas Dalam Terhadap Tingkat Kecemasan Pada Lansia Yang Menderita Hipertensi Di RT 03 RW 09 Kelurahan Slipi Palmerah Jakarta Barat. JURNAL KREATIVITAS PENGABDIAN KEPADA MASYARAKAT (PKM). https://doi.org/10.33024/jkpm.v3i2.3194
538. Wakefield, J. C. (2015). DSM-5 substance use disorder: how conceptual missteps weakened the foundations of the addictive disorders field. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12446
539. Wakefield, J. C., & Schmitz, M. F. (2014). Uncomplicated depression is normal sadness, not depressive disorder: further evidence from the NESARC. World Psychiatry. https://doi.org/10.1002/wps.20155
540. Walterscheid, B., Eshak, N., & Nugent, K. (2021). Altered mental status in a patient with psychiatric history: Medication noncompliance or medical etiology?. Journal of Investigative Medicine.
541. Wand, G. S. (2008). The influence of stress on the transition from drug use to addiction.. PubMed.
542. Weber, F., & Lehmann‐Horn, F. (2018). Hypokalemic Periodic Paralysis.
543. Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2012). Case Report: A Case of Acute Psychosis After Buprenorphine Withdrawal. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11cr07608
544. Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2013). 2824 – Acute psychosis and buprenorphine withdrawal: abrupt vs. progressive could make a difference. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77409-1
545. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
546. Weiss, B., Clarkson, T. W., & Simon, W. (2002). Silent latency periods in methylmercury poisoning and in neurodegenerative disease.. Environmental Health Perspectives. https://doi.org/10.1289/ehp.02110s5851
547. Westmoreland, B. F. (2001). Periodic Lateralized Epileptiform Discharges After Evacuation of Subdural Hematomas. Journal of Clinical Neurophysiology. https://doi.org/10.1097/00004691-200101000-00005
548. Wiederhold, B. K., Garmon, E. H., & O'Rourke, M. C. (2019). Nerve Block Anesthesia.
549. Wiglusz, M. S., Cubała, W. J., Nowak, P. M., Jakuszkowiak‐Wojten, K., Landowski, J., & Krysta, K. (2013). Sibutramine-associated psychotic symptoms and zolpidem-induced complex behaviours: implications for patient safety.. PubMed.
550. Wijdicks, E. F. M., & Clark, S. L. (2018). Treatment of Brain Injury-Associated Symptoms and Signs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190684747.003.0019
551. William, W., Pakpahan, C., & Ibrahim, R. (2020). Post-orgasmic Illness Syndrome: A Closer Look. Indonesian Andrology and Biomedical Journal. https://doi.org/10.20473/iabj.v1i2.34
552. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
553. Woert, M. H. V., & Chung, E. (2020). L-5-Hydroxytryptophan. CRC Press eBooks. https://doi.org/10.1201/9781003066736-65
554. Wright, S. L. (2020). Benzodiazepine Withdrawal. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197517277.003.0008
555. Wrightson, P., & Gronwall, D. (1999). Clinical picture after mild head Injury. https://doi.org/10.1093/oso/9780192629395.003.0005
556. Yang, B.-K., Yi, S.-R., Ahn, Y.-J., Im, S. H., & Park, S. H. (2016). Ischial Tuberosity Avulsion Stress Fracture after Short Period of Repetitive Training. Hip & Pelvis. https://doi.org/10.5371/hp.2016.28.3.187
557. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
558. Yasui‐Furukori, N., & Kaneko, S. (2011). Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2011.02211.x
559. Yates, S. J., Ahuja, N., Gartside, S. E., & McAllister‐Williams, R. H. (2011). Serotonin syndrome following introduction of venlafaxine following withdrawal of phenelzine: implications for drug washout periods. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125311413497
560. Yee, B. J., Liu, P. Y., Phillips, C. L., & Grunstein, R. R. (2013). Neuroendocrine aspects of sleep apnea. CRC Press eBooks. https://doi.org/10.3109/9781420020885-16
561. Yogaratnam, J., & Perera, M. A. L. (2013). <i>De Novo</i> delayed onset hypothermia secondary to therapeutic doses of risperidone in bipolar affective disorder. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125313507740
562. Yokoyama, H., Hirose, M., Nara, C., Wakusawa, K., Kubota, Y., Haginoya, K., Tsuchiya, S., & Iinuma, K. (2010). [A case of bipolar I disorder with autistic disorder showing "waiting-for-instruction" as a depressive symptom].. PubMed.
563. Yustiana, A. V., & Aryani, L. N. A. (2019). Gangguan psikotik akibat penggunaan ganja (cannabis): studi kasus. Medicina Journal. https://doi.org/10.15562/medicina.v50i2.123
564. Zaidi, A. N. (2005). Rhabdomyolysis After Correction of Hyponatremia in Psychogenic Polydipsia Possibly Complicated by Ziprasidone. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1e518
565. Zoorob, R., Kowalchuk, A., & Grubb, M. D. (2018). Buprenorphine Therapy for Opioid Use Disorder.. PubMed.
566. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c